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  ABSTRACT 
 
Introduction : In the caucasian population Cystic fibrosis is the most common life limiting 
genetic disorder with in incidence of approximately 1 in 2500  born in United Kingdom . 85% of 
those children have pancreatic insufficiency. There is paucity of data from India on the 
prevalence of cystic fibrosis,genetic profile of Indian patients and prevalence of pancreatic 
insufficiency. 
 
OBJECTIVES: 1)To determine the proportion of children with pancreatic insufficiency among 
children with cystic fibrosis attending paediatric respiratory clinic in a tertiary care centre in south 
India during the period  between September 2013-August 2014 .2)To compare the clinical and 
demographic characteristics of cystic fibrosis children who are pancreatic insufficient and 
pancreatic sufficient.3)To identify clinical variables towards development of a clinical score to 
predict pancreatic insufficiency.  
 
METHODS :  This prospective observational descriptive study was done on children with  cystic 
fibrosis between the age groups of 0-15 years. After informed consent ,clinical and demographic 
data was collected using a structured proforma. Pancratic insufficiency was diagnosed if faecal 
elastase level was <200 microgram/ gram of stool . Prevalence of pancreatic insufficiency was 
calculated as percentage with 95% CI. Comparison between pancreatic insufficient and sufficient 
gruops were done comparing clinical variables using Fishers exact chi square test . Potential 
variables for score development  are presented as RR (relative risk ) variables after  bivariate 
analysis which are included in multivariable regression analysis .Values with p < 0.05 are 
considered significant. 
 
RESULTS AND CONCLUSIONS: Pancreatic insufficiency was present in 62.4% ( 95% CI 
42.7-82.3) of 24 children . Additional 19% of patients were diagnosed to have pancreatic 
insufficiency by using faecal elastase test than what would have been detected if only classical 
history of steatoorhoea was used for diagnosis. Recurrent respiratory infections were present in 
100% of patients while  78.8%  had weight less than 5th centile on growth chart .Other  classic 
features of cystic fibrosis  like meconium ileus,  rectal prolapse, nasal polyposis were seen in only 
a minority of patients. Presence of malodorous stool, frequent passage of stool and lower 
(worse)Cooperman  score were more common amongst the pancreatic insufficient group 
compared to the pancreatic sufficient group and the difference was statistically significant. 
History of malodorous stool and frequent passage of stools (>/=3 times a day)  were the two risk 
variables identified for computing a clinical score to predict pancreatic insufficieny. A larger 
study with a higher sample size will be required to develop this  score. 
 
 
 
10 
 
 
 
Introduction 
           Cystic fibrosis (CF) is an autosomal recessive disorder caused by a mutation in 
cystic fibrosis transmembrane regulator gene which leads to defective epithelial transport 
of chloride and  results in  varied clinical features mainly of the respiratory system and GI 
tract. According to western studies 85% of children with cystic fibrosis have pancreatic 
insufficiency (PI). One Indian study   reported that the prevalence of malabsorption is  
80% in north India among cystic fibrosis children.  Loss of pancreatic exocrine function 
results in malnutrition, which has a negative correlation with lung function, clinical status 
and survival. It is also proven that patients who have pancreatic insufficiency have severe 
lung disease and malnutrition. Hence it is important to accurately and rapidly diagnose 
pancreatic insufficiency and treat maldigestion and optimize nutritional status. 
Diagnosing pancreatic insufficiency in younger age group with cystic fibrosis  is not 
always easy. Clinical criteria like bulky oily stools, insatiable appetite are considered the 
hall mark of fat malabsorption. But children may not always have these features. 
Malnutrition and failure to gain weight adequately, are taken as reliable clinical 
indicators to suggest pancreatic insufficiency in developed countries. However, there are 
many other reasons for malnutrition and poor weight gain in Indian children .This 
includes socioeconomic reasons, avoidance of many food items due to cultural or 
religious beliefs and non availability or non acceptance of energy rich food items. In 
addition chronic airway inflammation and recurrent infective exacerbations lead to 
malnutrition.   
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                     In our hospital, only those cystic fibrosis children with classical symptoms 
of steatorrhoea were screened for fat malabsorption. Pancreatic supplements were offered 
to only these children. In a pilot study of clinical features of Indian children with CF 
(mainly from South India) done in our instituition,only 26.7% were found to have 
symptoms of fat malabsorption(unpublished data).This is stark contrast to 85% 
prevalence of PI in Caucasian CF children. In a study consisting of children from 
Northern part of India and Pakistan prevalence of malabsorption was 80%(1) .The 
difference could be due to the difference in the causative mutation in the Indian 
population  . Other possibility is that we are underdiagnosing PI , when diagnosis is based 
only on clinical features, Hence the need for this study to estimate the true proportion of 
PI amongst Indian CF children. 
Stool elastase test ,  which is a sensitive and specific test for the purpose is costly and is 
not widely available. Many   small hospitals will not be able to get  this test done .Hence 
it is important to develop a scoring system based on clinical features and simple lab tests 
to reliably predict pancreatic insufficiency. This will be a useful tool for clinicians to 
identify those who present with PI and those who develop PI during the course of illness  
and start treatment early.   
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AIMS AND OBJECTIVES  
 
Primary Objective:   
        1.    To find out the proportion of children with pancreatic   insufficiency (PI) among     
Cystic Fibrosis patients aged 0-18 years attending a tertiary care centre in South India,                                       
using faecal elastase test. 
 
 
 Secondary Objectives: 
 To correlate the demographic and clinical features  with presence of pancreatic 
insufficiency 
 To develop a clinical scoring system to predict pancreatic insufficiency in 
children with Cystic Fibrosis 
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Overview of Cystic fibrosis 
 
Historical perspective 
                   
                 Cystic fibrosis (CF),   is an autosomal recessive genetic disorder which has 
deleterious effects on vital organs like  lungs,  liver, pancreas  and intestine. It is 
characterized by abnormal transport of sodium and chloride across an epithelium, leading 
to viscous and thick secretions. The name cystic fibrosis is given in reference to the 
characteristic scarring and cyst formation within the pancreas, and   was   first used in the 
1930’s. However the first description of cystic fibrosis   dates back to 18th century when 
the literature from Germany and Switzerland warned the association between salt loss 
and the illness. Farber and Scwachmann postulated that cystic fibrosis is a generalised 
abnormality of mucus secreting glands and suggested the term mucoviscidosis(2). 
                It was in 1930 Dorothy Hansine Anderson published an article that first 
described cystic fibrosis . She described characteristic features of CF affecting pancreas. 
She also correlated  the intestinal and  lung findings which are  characteristic of  cystic 
fibrosis. She was the one to hypothesize that cystic fibrosis  was a recessive disease and 
pioneered in the use  of  pancreatic enzyme replacement as a treatment for affected 
children. 
                In  1953 , ‘Paul di Sant'Agnese’  noted  elevated  salt content  of sweat in 
people with cystic fibrosis after observing dehydration in  children during a New York 
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City heat wave. He postulated that the concentration of sweat electrolytes were 2-4 times 
higher in cystic fibrosis and chronic pancreatic insufficiency. He also identified that the 
symptoms are initially due to   pure salt loss and the subsequent loss of  extracellular 
fluid volume(3).  
                  The specific faulty gene which is responsible for CF was first identified in 
1985 by Dr Francis Collins and Professor Jack Riordan(4). In early years nutritional 
support and airway clearance was the mainstay of treatment.  
                 Subsequently ‘Cystic Fibrosis Foundations Patient Registry’  founded  by 
Warren Warwick from  1964  had  shown  an increase   in median  survival from 14 years 
in 1968 to 20years in 1977(5). There was steady improvement in the condition and 
survival of many people with cystic fibrosis. New techniques of physiotherapy with new 
devices were described in 1980s when exercise was given more attention. The feasibility 
of eradication of Pseudomonas aeruginosa using nebulized tobramycin and colimycin 
was  confirmed in a controlled trial done in Denmark(6), Later In 1983, Paul Quinton 
demonstrated  that the chloride impermeability  in sweat glands was the underlying basis 
for increased sweat electrolyte concentration in children suffering from cystic fibrosis(7) 
              In 1989 , the cystic fibrosis gene was detected by teams headed by ‘LapCee 
Tsui’ who termed the gene as Cystic fibrosis Transmembrane conductance  regulator 
gene (CFTR) (8). Studies in early 1990’s showed that Dornase alfa improves mucociliary 
clearance of CF sputum by breaking down extracellular DNA released from neutrophils 
which accumulates in response to chronic bacterial infection of airways(9). Subsequently 
clinical studies demonstrated the clinical safety and efficacy of dornase alfa in improving 
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lung function and decreasing pulmonary exacerbations.The first drug designed to target 
cystic fibrosis is the mucolytic Pulmozyne and the Food and Drug Administration 
approved the use of it(9). With early recognition of disease, aggressive treatment of 
malabsorption and respiratory infections, the mean life expectancy has improved from 
early childhood to 37.5 in 2005 . 
               Today, diagnostic  tools from antenatal period is available. Antenatal screening, 
newborn screening and carrier testing of CF are being done. This screening tests along 
with good understanding of disease  and treatment strategies, has given way to an 
extended life expectancy and better quality of life. Recent   developments in medical 
research and technology will continue to provide hope for the future for care and drug 
therapy. 
One such milestone is the development of Ivacaftor, a new drug that acts as a potentiator 
and activates defective CF transmembrane conductance regulator (CFTR) at the cell 
surface(10). The primary target for this therapy is mutated CFTR G551D. 
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Prevalence  
 
World wide 
                                
                 Cystic fibrosis is the most commonly found genetic disorder in the white 
population accounting to 1 in 3000 live births(11). In the Asian Americans the prevalence 
is 1 in 31,000 individuals whereas   in Asians it accounts to 1 per  90000. The estimated  
prevalence of CF among Indians residing in UK is 1 in 10,000 to 1 in 12,000  and in the 
USA is 1 in 40,000 respectively(12). 
The prevalence of cystic fibrosis  in South Asians was estimated to be 1 in 9200 as per 
CF database(13) 
India 
                     Cystic fibrosis was initially considered to be non prevalent  in India as it 
was assumed that it was a disease of Caucasian  population. Recent publications suggest 
that cystic fibrosis is   more common  amongst those of  Indian origin than was 
previously assumed .Now it is clear that many cases are missed or underdiagnosed(1) . 
Indian children with cystic fibrosis are diagnosed in an advanced stage. It  was in 1968 
when the first case of cystic fibrosis was reported(14) . A recent  study in India was done 
to account  the prevalence of CF among Indians based on carrier frequency of del 508 
mutations in samples of cord blood . The CF  prevalence according to this study is  
1/43,321 to 1/100,323.                              
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Age Distribution 
               Age distribution of disease in any population is a function of birth rate , 
mortality rates and survical. According to ‘Cystic Fibrosis Foundation, patient registry 
Yearly report 2004’ in United States 42% were aged over 18, likewise 47% were aged 
above 18 in Canadian population. 
 
Age at diagnosis: 
                    In the west 70% of the CF patients  are diagnosed before the first birth day 
and 90% before the eighteenth birth day(15). Late diagnosis there is usually  associated 
with a milder clinical syndrome which includes a better lung function, nutritional status 
and a lower prevalence of colonization by Pseudomonas aeruginosa . 
                     In Indian scenario the median age of diagnosis is  54 months (16) indicating 
the  low index of suspicion for CF in India  causing a delay in the diagnosis of  the 
disease resulting in  the high the morbidity and mortality. This caries implication when 
considering studies looking at long term benefit of neonatal screening for cystic fibrosis. 
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Pathogenesis  
The fundamental pathophysiological mechanisms in cystic fibrosis include  
1) Failure to clear mucus secretions 
2 )Thick mucus secretions due to lack of water content  
3) Raised  content of salt in the sweat and other serous secretions 
The basic underlying pathophysiological mechanism is that the epithelial cells 
membranes in CF are unable to produce chloride ions in response to cyclic adenosine 
monophosphate signals. The net result would be large quantity of sodium ions   being 
absorbed through these epithelial  membranes. 
The following figure shows ‘ the net ion exchange across normal and cystic fibrosis 
airway epithelia under basal conditions’(17).  
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The expected  net flux of water would be away from the lumen of the airway into the 
submucosa as water follows salt movement  .This net flux would be more across CF 
epithelia. The raised  sodium absorption by the CF cells is in association  with  a raise  in 
amiloride sensitive sodium conductance across the apical membrane This causes  raised 
Na-K ATP ase sites at the basolateral membrane .The c AMP mediated apical membrane 
conductance of chloride associated with CF transmembrane regulator (CFTR) has no role 
in CF epithelia, but an alternative Calcium  activated chloride conductance is present in 
normal and as well as  CF cells.It is also hypothesized  that CF cells have reduced  ability 
to produce chloride and absorb sodium in excessive amounts reducing  the water present 
to hydrate secretions and allowing them to clear from airway lumen. 
Classes of CFTR mutation 
The primary function of CFTR is Cyclic AMP stimulated protein kinase A regulation of 
chloride conductance. In various mutations of CFTR this function is absent in the 
epithelial cells. 
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Table  shows  class of mutations, its effect on CFTR production and amount of 
CFTR available 
Class of  mutation CFTR production and function 
Class I Deficiency of protein production with premature  
termination of CFTR protein generation. 
There is production of few functioning CFTR protein 
Class II CFTR Protein trafficking  weakness so that it fails to 
reach the apical surface membrane where it is intended to 
function. 
Class III Defective regulation of gene which allows movement of 
chloride in and out of the cell. CFTR is not activated by 
ATP/cyclic AMP 
Class V Defect in splicing  with decrease in production of normal 
CFTR 
 
CFTR mutations fall into 6 classes along with some  overlap  . Those   persons  with class 
I, II, III on an average have  decreased  survival than  class IV, and V which  have mild 
genotypes.  
The following figure shows categories of CFTRmutations(17) 
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MUTATIONS  
In most European populations CFTR gene mutations are well characterized. In many 
Western- European countries, CFTR mutations were identified in greater   than 95% of 
persons with CF. 
The most common mutation causing CF is F508 del , the frequency of which is  nearly 
70% in many parts of Europe. 
Few mutations,   like ‘F508del, N1303K, W1282X and 3120+1G>A’ are predominant in 
Middle east countries and in  many other parts of  the world.(18). 
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F508del mutation is much more common in Europe as compared to the Middle East and 
it is relatively common in Israel and Lebanon countries as well. It is also noticed that, 
3120+1G>A is more in individuals of African origin, which could have possibly spread 
from the   African to Arabic populations. 
Study done in AIIMS Delhi showed that the frequency of F508del mutation is 19% which 
is noted to be less than that was found in Caucasian population. 33.3% of F508del – 
homozygous mutation was shown in Mutation analysis study done in Kashmir (1) . 
Classification of CF phenotypes(19) 
1.Classical cystic fibrosis: 
The clinical features of recurrent chest infections, malabsorption associated with 
pancreatic insufficiency, presentation in infancy with rectal prolapse,  meconium ileus or 
unexplained malnutrition are included under classical CF 
Pancreatic sufficient patients are not excluded from classical CF category although 
pancreatic insufficiency is seen in 85-90% of CF children. Positive sweat test and /or two 
CFTR mutations is diagnostic. Appropriate therapy for such patients should be ensured 
soon after diagnosis. 
2.Atypical (non classic ) cystic fibrosis 
Children who do not present with full spectrum of clinical features associated with 
classical CF are grouped under atypical CF. There may be single organ involvement. 
Sweat testing may be normal or negative and CFTR analysis may reveal one, two or no 
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mutations. In patients with atypical CF who have two identified mutations one may be 
mild mutation resulting in partial CFTR expression and function. 
3.CFTR related disorders 
CFTR related disease is a term coined to classify ‘non CF conditions that carry higher 
incidence of CFTR mutations that could be expressed by chance but have no other 
indicators of either classical or atypical CF. 
 Examples include: 
Allergic bronchopulmonary aspergillosis 
Acute or recurrent pancreatitis 
Isolated obstructive azospermia 
Chronic rhinosinusitis 
Disseminated bronchiectasis 
Diffuse panbronchiolitis 
Heat exhaustion 
4.Genetic Predisposition for CF with no clinical sequelae 
This referrers to group of individuals with the genetic potential to develop CF but in 
whom on detailed assessment there is no evidence of end organ dysfunction. There is a 
potential that clinical features will emerge with time but there is insufficient clinical 
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evidence to label the carrier of gene mutations with a disease. The role of prophylactic 
therapy in this situation is unclear. 
Clinical presentation in  cystic fibrosis 
Symptoms related to cystic fibrosis may present at any time   of life with tremendous 
variability and overlap of symptoms and timing between  one patient to another. 
The following figure shows average age of onset of clinical manifestations of cystic 
fibrosis in children(17) 
 
Gastrointestinal symptoms 
Meconium  ileus is the neonatal manifestation of approximately 15% of cystic fibrosis  
infants. The frequency is more  in siblings born following  birth of a child  having  
meconium ileus and is strikingly more common  in monozygotic twins attributing to a 
genetic  association from one or more genes(17) . Abdominal distension, vomiting, 
failure to pass meconium occur in first 24- 48 hours after birth. Abdominal radiographs 
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show distension of bowel with multiple   air fluid levels and commonly presence of 
ground glass material in the lower abdomen. The presence of homozygous  delta F508 
deletion, in CF patients, is strongly associated with the presence of Meconium Ileus(20)  
and pancreatic insufficiency is found in all children homozygous for ∆F508. 
Gastrograffin enemas or surgery is needed to treat this condition. There have been  no 
differences in survival between MI and non-MI patients as per recent articles.(21).  
85-90% of children with meconium ileus develop pancreatic insufficiency which 
manifestes at birth or around the first year of life (16). 
Biliary tract 
Upto 30% of individuals with Cystic fibrosis have dysfunction of liver  and  is often 
recognised in the 1st 15 years of life . Symptoms of  biliary cirrhosis are detected in only 
5-7% of patients. Clinical manifestations of biliary tract  include hematemesis from 
esophageal varices, icterus, ascites,  and  features of  hypersplenism. There are reports of 
neonatal hepatitis picture as well(22).  Cholelithiasis leading to biliary colic   may be 
present in the 2nd decade or later. Liver disease is independent of genotype but is found 
in association   with pancreatic insufficiency and meconium ileus. Cirrhosis, ascites, 
portal hypertension are the other hepatic manifestations of Cystic fibrosis. 
 Cystic fibrosis-related liver disease (CFLD) is defined if ‘in a one year period, if at least 
2 of the following findings  are present on  at least 2 consecutive examinations’ 
(1) “Ultrasound confirmed hepatomegaly;  
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(2) Elevated serum levels of alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, gamma-glutamyltransferase; and  
(3) Ultrasound abnormalities other than hepatomegaly like increased and heterogeneous 
echogenicity, nodularity, irregular margins, splenomegaly” icterus, ascites,.  
Fatty liver on sonological examination is not considered as diagnostic criteria for CFLD.. 
If there are classic signs like splenomegaly, esophageal varices in addition to 
characteristic ultrasound findings of liver cirrhosis like coarse echotexture, nodularity, 
features of portal hypertension, evidence of porto systemic circulation, CFLD patients are 
classified as cirrhotics. 
Pulmonary manifestations 
Cough is the most constant symptom of pulmonary involvement which  may be initially 
dry and hacking but subsequently becomes loose and productive. Expectorated mucus is 
usually purulent. Some patients remain asymptomatic for long periods or seem to have 
prolonged but intermittent acute respiratory infections. Others acquire a chronic cough in 
the first weeks of life, or they may have repeated episodes of  pneumonia . Extensive 
bronchiolitis accompanied by wheezing is a frequent symptom during the first years of 
life. There are case reports on clinical presentation of CF as recurrent bronchiolitis in 
infants(23). As lung disease slowly progresses, exercise intolerance, shortness of breath, 
and failure to gain weight or grow become obvious . Exacerbations of lung symptoms 
very   often require repeated hospitalizations for effective treatment. Cor pulmonale, 
respiratory failure, and death eventually supervene unless lung transplantation is 
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accomplished. Colonization with B. cepacia and other multidrug-resistant organisms may 
be associated with particularly rapid pulmonary deterioration and death. 
The rate of progression of lung disease is the chief determinant of morbidity and 
mortality. The course of lung disease is largely independent of genotype . Severe 
mutations tend to be associated with more rapid progression. A few mutations may 
substantially or even fully spare the lungs. Male gender and exocrine pancreatic 
sufficiency are also associated with a slower rate of pulmonary function decline(17) 
Early physical findings include increased antero posterior diameter of the chest, 
generalized hyper resonance, scattered or localized coarse crackles, and digital clubbing. 
Expiratory wheezes may be heard, especially in young children. Cyanosis is often a late 
sign. Common pulmonary complications include atelectasis, hemoptysis, pneumothorax, 
and cor pulmonale which usually appear beyond the 1st decade of life. 
Respiratory infection and pathogens 
                The organism most frequently isolated from the sputum culture in cystc fibrosis 
patients is Pseudomonas aeruginosa. The prevalence of P.aeroginosa infection varies 
between countries and treatment centres within countries. Of all the factors that affect the 
infection rates the most important factor is the age .The prevalence of Pseudomonas, 
Burkholderia cepacia, Aspergillus species increase with age. Staphylococcus aureus 
colonisation remains constant throughout  life(19). 
            In United States , 57% of Patients had Pseudomonas in their sputum culture or 
other respiratory cultures in  2004. In the UK paediatric centres in 2003, colonisation 
rates ranged from 3% to 47%(19). 
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           In an Indian study done by Kabra et al(24)  P. aeruginosa was  found as an 82% 
culture positive patients .Its  rate of infection was significantly higher as compared to the 
other organisms in CF patients. 
 
Paranasal sinus involvement: 
                  Even though the paranasal sinuses are virtually always opacified 
radiographically, acute sinusitis is infrequent. Nasal obstruction and rhinorrhea are 
common can be either caused by inflamed, swollen mucous membranes or, nasal 
polyposis. Nasal polyps manifest between 5 and 20 yr of age. The  mean age of survival 
of people with cystic fibrosis worldwide has increased from 2 in 1950s to 37 years 
currently with roughly half of all CF individuals being of adult age. Survival depends 
upon both pulmonary and nutritional status. 
Gastrointestinal Reflux Disease 
                  Gastroesophageal reflux (GER) is found to be common in children and adults 
with CF.  GER is also associated with reduced pulmonary function. In individuals with 
CF it is still unclear whether increased incidence of GER the primary phenomenon or it is 
secondary to the disease. The pathophysiology of increased GER in CF is still not known. 
                 Findings of the Study done at Cottingham, UK showed that although weak 
acid GER is common in children with cystic fibrosis . GER is the primary phenomenon 
and it is not secondary to cough. Around one third of the children with CF have bile acid 
in saliva. Bile acid in saliva is an indication for increased risk for aspiration. They 
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recommended that the impact of salivary bile acid and potential risk aspiration on 
individuals with CF needs to be investigated further(25). 
It was also found that the chest physiotherapy given for postural drainage in different 
positions may exacerbate GER in infants with cystic fibrosis . Study done by Ralf G 
Heine et al in Royal Children’s Hospital, Australia did not find any correlation between 
the severity of the lung disease and the severity of GER. All infants who had significant 
GE reflux found to have normal chest x rays. The pathological reflux seems to be present 
even before lung disease is established(26). 
 
CF Related Diabetes 
After 10years of age, hyperglycemia occurs more frequently. It is found to a higher 
prevalence in females and in individuals with F508del mutation. Ketoacidosis is 
uncommon. Impaired insulin secretion and insulin resistance are the underlying 
pathology in CF with hyperglycaemia. When the child becomes 8-10year of age, an 
annual modified 2 hour oral glucose tolerance test is advised as part of routine screening.. 
HbA1C level should be checked once a year (17). 
Vitamin D deficiency in cystic fibrosis 
                         Vitamin D deficiency is common in individuals with cystic fibrosis due to 
impaired absorption of fat-soluble vitamins, decreased sunlight exposure, and suboptimal 
intake of vitamin D-containing foods  and supplements. Vitamin D deficiency in cystic 
fibrosis has been associated with decrease bone mass in children and failure to achieve 
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adequate  expected bone mass in adults. It has been shown to be the major contributor of 
bone disease in children(27). Also it may have impact on other comorbidities in cystic 
fibrosis. In a retrospective study done in Australia the prevalence of vitamin D deficiency 
in children with cystic fibrosis was found to be 15.54%(28). 
Causes of hypovitamiosis D in cystic fibrosis: 
The following figure demonstrates various causes of vitamin D deficiency in children 
with cystic fibrosis. 
 
 
CF and  Kidney Disease 
 CFTR gene is located in the proximal tubules of kidney, its dysfunction precipitates low 
molecular weight proteinuria. Kidney disease in CF is predominantly secondary to 
exposure to multiple aminoglycosides, immunosuppressants, non steroidal  anti 
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inflammatory agents. Aberration in transport of sodium chloride, Pseudomonas 
colonization and development of Cystic Fibrosis Related Diabetes (CFRD) requiring 
insulin can result in nephropathy(3). 
Evaluation of renal disease include measurement of serum creatinine and Creatinine 
Clearance,indirect measurement of  GFR using Cystatin C,early indicators of Kidney 
disease like NGAL( Neutrophil Gelatinase associated lipocalin) and KIM( Kidney Injury 
Molecule) 
Clinical Presentation of Cystic fibrosis in India 
                Indian Cystic fibrosis patients predominantly present with  malnutrition 
secondary to respiratory and gastrointestinal problems. Amongst this varied clinical 
presentation, respiratory involvement is predominant manifestation(17). In one Indian 
study almost 94% of cystic fibrosis patients presented with respiratory symptoms 
followed by nutritional abnormalities and pancreatic dysfunction amounting to  21% and 
4% respectively(24).In the same study the pancreatic abnormalities  were observed  
primarily  in older  age group children CF children.  Our unpublished data on clinical and 
genetic profile of CF children showed that among 22 CF children studied 86% had failure 
to thrive, 82% had recurrent respiratory tract infection, 41% had steatorrhoea at the time 
of presentation. 
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Diagnosis   of Cystic Fibrosis 
 
The diagnostic criteria for cystic fibrosis(29). 
Presence of typical clinical features (respiratory, gastrointestinal, or genitourinary)  
 OR  
 A history of CF in a sibling  
 OR  
 A positive newborn screening test  
 PLUS  
 Laboratory evidence for CFTR dysfunction:   
Two elevated sweat chloride concentrations obtained on separate days  
OR  
Identification of two CF mutations   
OR  
An abnormal nasal potential difference measurement” 
 
Sweat chloride estimation for diagnosis of Cystic fibrosis 
Children with CF secrete excessive salt in their sweat was reported by Dr. Paul A. 
diSant’Agnese in 1953 after observing dehydration in these children during a New York 
City heat wave (3) 
Sweat test was introduced in 1959 and since then it has remained  the "gold standard" 
diagnostic test for cystic fibrosis. Sweat testing  quantifies the chloride level  in the 
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sweat. Even though genetic mutation analysis are available, sweat chloride level 
estimation remains the standard test for diagnosing CF. 
 Pilocarpine iontophoresis  is executed  to collect the sweat and analysis of chloride 
content is done biochemically . 
To carry out  this test pilocarpine is injected into the skin of forearm to stimulate the 
sweat glands in the forearm.An electric current is used for the purpose. Sweat testing is 
difficult in the first two weeks of life in view of low sweat rates. But it is recommended 
that sweat testing can be done any time after the first 48hours of life (17) 
Positive results should always be confirmed. If the test is negative, test should be 
repeated if suspicion of CF remains. 
Interpretation of Sweat chloride results (30) 
In infants more than 6 months of age, sweat chloride test result showing value less than 
or equal to 39 mEq/L probably suggests that cystic fibrosis is not present. 
 
Value between 40 - 59 mEq/L implies that  CF is likely to be present may not be  
conclusive and it suggests further testing is needed to confirm the diagnosis. 
If the value is 60 mEq/L or more, it is diagnostic of CF when 1 or more other criteria  is 
present 
In individuals with normal exocrine pancreatic function the chloride concentrations in 
sweats are somewhat lower but usually it remain within the diagnostic range. In 
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conditions like eczema (atopic dermatitis), , malnutrition ,failure to thrive , ectodermal 
dysplasia ,deprivation are associated with false positive results whereas conditions like 
malnutrition, edema, insufficient sweat quantity, hyponatremia are associated with false 
negative results. 
Diagnosis by Sweat Conductance 
                 Sweat chloride estimation by pilocarpine iontophoresis requires great skill on 
the part of technician. Prevention of evaporation of sweat, determining sweat weight with 
chemical balance and calculation of chemical composition needs more precision and 
time. The macroduct sweat collection system avoids some of these problems. The 
macroduct sweat collection system consist of the Webster Sweat Inducer, Macroduct 
Sweat Collector and the Sweat –Check Analyzer where conductance is measured instead 
of chloride level. 
                   Readings are obtained in the following categories Upto 60 mmol/L – normal 
range, 60 to 80 mmol/L – borderline, >80mmol/L - abnormal . Applicability of this for 
screening for cystic fibrosis and as a diagnostic test has been verified in many 
studies(31). This commercially available test was used in our study for diagnosis of CF. 
In a study published in the Turkish journal of paediatrics, the results by these 2 methods 
were compared between 59 CF patients and 69 non CF patients. The Spearmen 
correlation test revealed strong correlation between conductivity test and chloride level 
(r=88%,p<0.001)(32) . 
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Other method for sweat testing 
Newer method of  quantitative sweat electrolyte determination is CF Quantum test  which 
is a swift and simple method .In a study done for dianostic accuracy of CF Quantum test   
the sensitivity of cystic fibrosis quantum test was 100% with 95% CI of 94-100% while 
the specificity was 96% with 95% CI of 89-99% respectively(33). However in three 
centre multicentre study the percentage of  invalid tests was higher in the CFQT method 
(16.5%) compared to conventional sweat testing (3.8%) (p<0.001). CF Quantum test still 
requires refinement to improve the dianostic accuracy and reduce the number of valid 
tests. 
Diagnosis by nasal potential difference: 
The following diagram is the schematic representation of  recording nasal potential 
difference and the anterior nasal cavity showing the site of measuring Nasal potential 
difference(34). 
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Nasal potential difference(NPD) is a test that quantifies   the voltage  difference  across 
the nasal epithelium. It  results from transepithelial ion transport and reflects in part 
CFTR function. This test  certainly serves the purpose of  diagnostic tool in cases where 
abnormal CFTR function  is suspected and the other tests are inconclusive. NPD is 
research and diagnostic tool, and is used to assess the efficacy of new treatments such as 
gene therapy and ion transport modulators. 
 
Genetic testing for CF  
The CFTR gene is located on q31.2 locus chromosome 7.  F508 del is the most common 
mutation caused due to deletion of 3 nucleotides  resulting in loss of phenylalanine at 
508th position on the protein..  
Genetic testing for CFTR for diagnostic purposes is done when the sweat chloride 
concentration is unavailable or not confirmatory  . 
In the following distinctive conditions, Molecular testing of CFTR gene is regarded as the 
primary diagnostic test(35). 
 Infants who have neonatal complications like meconium ileus as they cannot 
produce adequate quantity of sweat for sweat electrolyte  test 
 To test sibling of the affected patient who is symptomatic , to identify CFTR 
mutations in both. 
 To test the high risk fetus in the antenatal period 
 Antenatal  diagnosis in  low-risk fetus with  ultrasound detected echogenic bowel 
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 Screening of the neonate 
 
Targeted mutation analysis 
5T/TG tract analysis 
CFTR related disorders can be confederated with the poly  T tract found on the exon 8 of 
the CFTR  gene .5T, 9T and 7T are the three common variations  of the poly T tract. 9T 
and 7T are  considered as the polymorphic variations while 5T is aforethought as a 
variably penetrant mutation. The 5T variant is thought to decrease the efficiency of intron 
8 splicing.  
The TG tract lies just 5' of the poly T tract. It consists of a short string of TG repeats that 
commonly number 11, 12, or 13. A longer TG tract (12 or 13) in conjunction with a 
shorter poly T tract (5T) has the strongest adverse effect on proper intron 8 splicing’(36) . 
Sequence analysis 
 Sequencing of all exons, intron/exon borders, promoter regions and specific intronic 
regions detects more than 98% of CFTR mutations(37). 
Deletion analysis. 
 Multiplex ligation-dependent probe amplification  can detect deletions not identified by 
aforementioned  analysis. However, mutation detection rate is unclear. 
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NEWBORN SCREENING FOR CF 
The rationale for newborn screening is that early detection of CF may lead to earlier 
intervention and improved outcomes because affected individuals are diagnosed, referred, 
and treated earlier in life as compared with individuals who are diagnosed after 
presenting with symptomatic CF.  
Two methods are employed for new born screening in cystic fibrosis 
Immunoreactive trypsinogen Assay:  
                  Elevated levels of IRT are quantified by either Enzyme Linked 
Immunosorbent assay or radioimmunoassay. Levels of IRT fall rapidly during infancy, 
hence a negative test is not informative, the test being more sensitive than specific(38). 
DNA assay: 
                 Genetic analysis for mutations in the CF gene  can be used as a primary or 
secondary screen to confirm and support  the diagnosis in patients with non diagnostic  
IRT assays (IRT/DNA protocol)(39). 
The purpose of a Neonatal screening (NS) for CF is to reduce the mortality and 
morbidity. The benefits of early diagnosis should countervail any possible  disadvantage 
from screening of both the unaffected and affected babies. The NS programmes for CF 
are existing for more than 30 years now.. Clinical outcome studies by Doull et al have 
reported that there is decrease  in hospital admissions during the first year of life and 
early improvement of nutrition for screened infants . Another systematic review 
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concluded neonatal screening of cystic fibrosis  may results in better survival and 
outcome of the child (40)  .  
The neonatal screening along with  identification of most asymptomatic patients offers 
the plausibility  of early precautionary  treatment and genetic counselling . The 
combination of IRT and PAP (pancreatitis associated protein)  or Fecal elastase  can be 
used for early screening of neonates. 
Hurdles in  Diagnosis of CF in India 
 
                  Under diagnosis of Cystic fibrosis  in India has various reasons. The 
respiratory manifestations mimic a variety of conditions like tuberculosis, bronchitis, 
pertusis, reactive airway disease , immune deficiency diseases , bronchiectasis, etc. The 
index of suspiscion  is low in India due to high prevalance of infectious diseases like 
tubeculosis and reactive airway disease and the diagnosis of CF is missed . In addition to 
that the varied presentation  and  severity of  disease further complicates the diagnosis of 
cystic fibrosis.Hence, CF may be far more common in people of Indian origin than  what 
was previously thought but is under diagnosed or missed in majority of cases.  
                  Sweat chloride estimation   used as the diagnostic tool  for suspected CF 
patients is not done in most parts of India due to lack of facilities .Two sweat chloride 
values are required as per diagnostic criteria which further makes it less suitable for 
Indian patients owing to the high cost of test. It is not cost effective to set up diagnostic 
facilities in many centers across the country. As the patient need to come to the facility 
for testing, it adds another hurdle in the diagnostic challenge. 
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               The suspected CF cases with a borderline sweat chloride concentration (40-60 
mmol/L) presents another  diagnostic difficulty. It is not entirely clear if we can apply the 
same cut off values of sweat chloride to Indian population. It has been observed that 
many Indian patients with typical clinical features and sometimes positive CFTR 
mutation have lower sweat chloride level..Genetic mutation analysis can contribute to 
diagnosis of CF in case of intermediate sweat chloride levels(41). 
 
MANAGEMENT OF CF 
Cystic fibrosis is a multisystem disease which requires a holistic approach to care by 
multidisciplinary team. It is best done CF care centers involving physician, dietician, 
nurse, respiratory therapist, occupational therapist, psychologist. Nutritional and 
pancreatic insufficiency management will be discussed in detail later. 
Pulmonary therapy 
Antibiotics:  
Course of pulmonary disease is heralded by chronic respiratory infections with periodic 
exacerbations. Oral azithromycin is recommended as prophylaxis. Long term treatment 
with nebulized antibiotics (Tobramycin and Aztreonam) particularly targeting against the 
common colonizing pathogens in CF like pseudomonas. This decreases the number of 
exacerbations, hospital admissions while improving improves the lung function.. 
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Agents to promote airway clearance(19): 
Inhaled DNA ase: cleaves the denatured DNA released by neutrophils that are 
degenerated. This thereby decreases   the viscosity of pulmonary secretions. 
 Inhaled hypertonic saline 
The high osmolality of the solution draws water from the airway epithelium to re-
establish the aqueous surface layer which is deficient in CF. 
Chest physiotherapy 
It is strongly recommended to clear the airway secretions and is the mainstay of treatment 
of bronchoectasis. 
vaccines 
Pneumococcal and Influenza vaccine are recommended in all children with CF to prevent 
exacerbations 
CFTR modulators: 
Ivacaftor:  It is recently designed drug  to treat patients with  a G551D mutation on at 
least one of CFTR genes. In phase 3 RCTs Ivacafter has improved the mean percent 
predicted forced expiratory volume in one second (FEV1), decreased sweat chloride 
levels and improved pulmonary symptoms resulting in weight gain. 
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Future Therapies for CF 
Gene Therapy (19) 
Cloning of CF gene can be performed though  non viral and viral gene transfering agents 
and transferred  to both bronchial and nasal epithelium. 
Currently available non viral gene transfer agent is vector specific human CFTR. m RNA 
Adeno Associated Virus is currently most commonly used vector for CF gene therapy , 
however repeated administration remains an unsolved problem  
Scope of Stem cell therapy in relation to cystic fibrosis(19)  
Following therapeutic  measures are under research trials 
 Stem cells derived from the bone marrow can be injected intravenously 
 Topical administration of  the exvivo corrected stem cells to lung 
 Integrated viral vectors can be targeted  on  resident stem cells of the airway’ 
  Pancreatic insufficiency in Cystic fibrosis  
Pathophysiology of pancreatic insufficiency (PI) 
             Pancreatic exocrine insufficiency is major complication of CF and an important 
cause of maldigestion.. The normal digestive process involves stimulation and production 
of pancreatic juice by acinar cells  and mixing of he undigested food with  pancreatic 
juice with  no duct outflow obstruction. Symptoms of malabsorption like oily stools, 
abdominal bloating, weight loss, would manifest if there is interruption in any of the steps 
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mentioned(42). Pancreatic enzyme secretion is stimulated during the cephalic  and gastric 
phases to a certain degree, but the most important stimulation occurs during the intestinal 
phase, when chyme enters the duodenum.   
 The presence of fatty acids, amino acids and gastric acid in the duodenum is the most 
potent stimulator of exocrine pancreatic secretion. Vagal and neural reflexes stimulate 
pancreatic secretion during the cephalic and gastric phases. During the intestinal phase, 
cells in the duodenal mucosa release CCK, which stimulates the secretion of pancreatic 
enzymes from acinar cells and secretin, which elicits water and bicarbonate secretion 
from ductal cells. 
               The pancreatic juice consists of bicarbonate and water secreted by ductal cells 
and several enzymes, secreted by acinar cells, with the specific capacity to digest 
proteins, carbohydrates and fat. In situations with reduced exocrine pancreatic function, 
the ability to digest fat is the determining factor that causes the most important symptoms 
and clinical complications because lipase, the major lipolytic enzyme of the pancreatic 
juice, is the pancreatic digestive enzyme with the poorest stability in the gastrointestinal 
lumen.  
              The destruction of lipase is even more rapid when the pH is below 4, which is 
often the situation in CF, in which the buffering of gastric acid is insufficient due to low 
bicarbonate excretion by the pancreas. Furthermore, there is minimal extra pancreatic 
lipolytic enzyme production, as opposed to the extra pancreatic capacity to digest 
carbohydrates provided by salivary amylase and intestinal oligosaccharidases or the 
proteolytic capacity provided by gastric pepsinogen. 
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Different causes of pancreatic insufficiency: 
The following figure demonstrates various causes of pancreatic insufficiency (43) 
 
 
Cystic fibrosis and pancreatic insufficiency 
 
                       Patients with cystic fibrosis who are pancreatic insufficient have severe 
lung disease, malnutrition and liver disease. They are more prone to have pancreatitis as 
well .CFTR  is an apical chloride channel  located  in the proximal duct epithelium that  
regulates active chloride transport across epithelial cell membranes and thus serves the 
function of pancreatic exocrine function. Deficient fluid secretion is apparent at all levels 
of pancreatic function and leads to pancreatic protein hyper secretion which may in turn 
result in protein precipitation and ductal plugging. An impaired chloride and bicarbonate 
secretion appears to account for this fluid secretion deficit. Individuals with pancreatic 
insufficiency have decreased or absent levels of pancreatic enzymes like amylase, lipase, 
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colipase and phospholipases. However, they have   increased or normal production of 
salivary and brush border amylases, brush border peptidases and lingual lipases, which 
accounts for increased monosaccharide absorption, increased amino acid absorption, and 
few residual lipolysis respectively(44) .Due to the CFTR  gene mutation , the chloride 
transport channel cease to function thereby resulting in accumulation of  dehydrated thick 
protein-rich secretions  which results in obstruction  in  the  proximal ducts. This in turn 
results in   secondary acinar cell destruction, fibrosis, and exocrine pancreatic 
insufficiency in 85% of the CF population . 
                   60% of children with cystic fibrosis present with pancreatic insufficiency at 
birth. They present with symptoms of chronic diarrhoea, malabsorption, steatorrhoea, 
insatiable appetite ,poor weight gain and varying degrees of  malnutrition(45). Pancreatic 
function  in CF worsens with advancing age. 
Genotype and pancreatic insufficiency 
                   
                    Pancreatic function has a direct correlation with the genotype of the CF 
patients. CFTR gene mutations may be classified as severe or mild with respect to 
functional status of the pancreas. Patients homozygous for two severe mutations 
experience severe clinical presentation including PI. Patients carrying at least one mild 
mutation such as R117H, 3171insC, A155P2, 138insL, 296 +IG-A, E92GK, E217G, 
2789 +5G-A, or 3849 +10kbC-T and others  are considered to be pancreatic sufficient 
(PS) and carry an overall prognosis that is vastly superior to CF patients with PI(46). 
Classes 1, 2, and 3 mutations responsible for   little or no chloride channel function, 
confer the PI phenotype. In contrast, classes 4 and 5   mutations that allow CFTR residual 
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function  confer the less severe PS phenotype. The PS phenotype occurs in patients who 
have one or two mild CFTR mutations, such as “R117H, R334W, R347P, A455E, and 
P574H”, whereas the PI phenotype occurs in patients with two severe alleles, such as 
delta” F508, delta I507, Q493X, G542X, R553X, W1282X, 621 + 1G----T, 1717-1G----
A, 556delA, 3659delC, I148T, G480C, V520F, G551D, and R560T”(47).  Pancreatic 
insufficiency generally develops within the first few months of life in patients with two 
class I or II Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutations. 
These classes of mutation are characterized by defective production or processing of the 
CFTR protein, and include delta F508, N1303K, G542X, G551D and others . 
 
Genotype and pancreatitis 
                     Pancreatitis is an infrequent complication of cystic   fibrosis. In  one of the 
case reports published  in 1975 pancreatitis was present in 0.5% of CF patients , all of 
them being pancreatic sufficient(48).In a large survey done among cystic fibrosis patients  
pancreatitis was diagnosed in 1.24% of patients of whom 56% were pancreatic sufficient 
and 25% had pancreatic insufficiency(49). This survey showed that patients with PS 
Cystic fibrosis had higher incidence of  pancreatitis as a complication(10.3%), compared 
to patients with PI Cystic fibrosis (0.5%). 
                 Sultan M et.al in their study on children with recurrent pancreatitis in  
Milwaukee, USA found that CFTR, SPINK1, or PRSS1 mutations were seen  in 48%, 
27%, and 24% of individuals with CF. 2 were homozygous for CFTR mutations, 6 were 
heterozygous and 4 of them had 5 T variants. 2 others patients had double heterozygous 
mutations in F508 del/2789 + 5G > A and F508 del/5T variant(50). 
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               Indian studies showed that phenotype of Chronic Idiopathic pancreatitis is 
associated with SPINK1 and CFTR gene mutations in Indian population(51).  
 
Diagnosis of Pancreatic Insufficiency in the context of Chronic pancreatitis (CP) 
                  The classical clinical picture of PI is   child presenting with foul-smelling, 
loose stools, weight loss, muscle wasting and flatulence. Advanced tests of pancreatic 
exocrine function can usually be avoided in patients with a well-established chronic 
pancreatitis diagnosis based on morphological findings and a clear clinical picture of 
pancreatic exocrine insufficiency ( PEI). A trial of pancreatic enzyme replacement 
therapy (PERT) based only on the clinical picture is recommended by several national 
societies when the clinical presentation is strongly suggestive of PEI. However, only 
relying on symptoms may lead to both the over- and under-diagnosis of PEI. Diarrhoea 
and weight loss may be due to conditions other than PEI, and PEI can also be present in 
the absence of overt steatorrhoea. 
                In addition to explaining and treating clinical symptoms, the second  rationale 
for the early diagnosis of PEI is to prevent complications of malnutrition. It is reasonable 
to assume that such malnutrition-related complications will be preceded by deficiencies 
of macro- or micronutrients detectable by routine blood tests. Theorotically serum 
nutritional markers can support the  diagnosis of pancreatic insufficiency  Deficiencies of 
several nutrients in blood tests have been demonstrated in CP, including apolipoproteins, 
total cholesterol, magnesium, lipid-soluble vitamins, retinol-binding protein, calcium, 
zinc and selenium, but the majority of these studies have not taken the exocrine function 
status of patients into consideration. Studies investigating the association between 
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nutritional markers and PEI in CP patients have demonstrated that deficiencies of lipid-
soluble vitamins are associated with an increased probability of PEI(52,53), as opposed to 
B12 and folate levels, which are not associated with PEI(54).  
The possibility of diagnosing PEI based on nutritional markers in the blood was recently 
studied in a cohort of 114 patients with Chronic pancreatitis, of whom 38 suffered from 
PEI (54).Hemoglobin, albumin, prealbumin and retinol-binding protein levels below the 
lower limit of normal magnesium levels below 2.05 mg/dL; and HbA1C levels above the 
upper limit of normal were all significantly associated with PEI. No PEI patient in this 
study presented with normal values for all of these parameters. The central conclusion 
that can be drawn from this study is that a normal panel of serum nutritional markers can 
exclude PEI with a high negative predictive value.  
 
Radiological diagnosis for pancreatic insufficiency in relation to pancreatitis: 
The probability of PEI in CP can also be estimated based on pancreatic imaging findings 
in the absence of more advanced tests of pancreatic function. Ductal changes on 
endoscopic  retrograde pancreatography, computerized tomography and endoscopic 
ultrasound (EUS) have been associated with decreased exocrine pancreatic function. 
 The diagnosis of CP by EUS is based on the demonstration of several different 
parenchymal (hyperechoic foci, hyperechoic strands, parenchymal lobularity and cysts) 
and ductal (pancreatic duct dilatation, irregular pancreatic duct contour, hyperechoic 
pancreatic duct margin, dilated side branches and intraductal calcifications) abnormalities 
defined in the Rosemont classification (55). A recent study demonstrated a clear 
correlation between the number of EUS criteria met and the probability of PEI. 
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Calcifications and main pancreatic duct dilatation were independently associated with 
PEI in a multivariate analysis, and the probability of PEI was > 80% if these features 
were present(56). 
Relation between nutrition and Lung function in CF 
                 Patients with cystic fibrosis are not only known to have  loss of fat in the stool 
but also have low energy intake in their diet . In the past all CF centres recommended low 
fat diet, until till mid 1980’s when acid resistant pancreatic enzymes were available. 
Research done in Toronto  had  reported that calorie dense diet with  no fat restriction  
given to patients with cystic fibrosis along  with additional  enzyme supplements, resulted 
in an improvement in the nutritional status and  longevity among these patients .A similar 
study was done in Boston which is a comparably large and experienced centre but results 
obtained  were inferior to the former study done in Toronto . 
                             Longitudinal studies with sufficiently long follow up period   have 
shown that young underweight patients have worst pulmonary function outcomes. Data 
from Cystic fibrosis foundation annual report shows that severe decline in FEV1(<40%) 
is associated with 61.2% of children whose weights are less tham 5th centile(57). 
                                 Thus in order to maintain  pulmonary health and  effective 
maintenance of its function  aggressive nutritional support should be provided  to all 
young cystic fibrosis patients with a goal to maintain  normal growth patterns . 
Improving nutrition and its effect on outcome of CF 
                An intervational  randomized double blind placebo controlled trial done in 
Europe showed that twelve month nutrition intervention with organised lipid matrix has 
improved  the growth status, muscle stores and Resting energy expenditure. Improvement 
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in nutritional status had a positive outcome in pancreatic insufficiency and mild lung 
disease(58). 
 
Pancreatic insufficiency  and it's relation to lung function in CF 
            CFTR gene responsible for the disease is located on the bronchial epithelium and 
gastrointestinal tract .In a cross sectional study (59) , Corey et al. in 1997 showed that the 
outcome among the cystic fibrosis patients with pancreatic insufficiency  was directly 
related to the severity of the  CF lung disease. This was further substantiated in study 
done by Schaedel et al  where they concluded that  many Pancreatic Sufficient patients 
had  mild pulmonary disease in the long term, compared to patients with pancreatic 
Insufficiency(60). A cohort study done showed a  significant difference( p=0.001) among 
patients with pancreatic sufficient and insufficient functional status in  FEVI,FVC 
values(61). This  individual group comparisions helped  to demonstrated that patients 
with pancreatic sufficient status had consistently better  lung function than compared to 
pancreatic  insufficient status. 
PI –relation to nutrition and growth pattern in CF 
 
Pancreatic Insufficiency is the major contributor of nutritional problems in children with 
cystic fibrosis. The early growth pattern of infants with CF is dependent on both the age 
at diagnosis and the quality of the   treatment they receive subsequently. Majority   of the 
patients with  pancreatic insufficiency manifest with early GI symptoms like oily stools, 
flatulence, bloating sensation etc., which if not recognized and treated early in infancy  
can lead to  inadequate weight gain and  complication secondary to malnutrition. In those 
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infants who were diagnosed by neonatal screening also tend to have have subnormal 
growth patterns during their  first year if there was a delay in the start of  treatment by 
more than a few weeks after birth Nutritional status in cystic fibrosis tends  to decline 
during early child hood. Subsequent growth pattern after infancy is normal if the 
pulmonary infections are prevented and intestinal malabsorptions effectively treated(62). 
 Data from the Cystic fibrosis Foundation (CFF) shows that the body mass index (BMI) 
percentile typically begins to decline at about five years of age but does not cross the 50th 
percentile   until about nine years of age(63).BMI target range for children with cystic 
fibrosis kis above 50
th
  centile. Children with BMIs between the 10th and 50th percentiles 
are generally considered at nutritional risk, and those with BMIs below the 10th 
percentile are in need of nutritional rehabilitation. Children with BMIs above the 85th 
percentile are considered overweight. Children who do no meet the targets for BMI and 
whose linear gowths are less than expected for growth potential should be given intensive 
counselling  to optimize  nutrition. Bone deformities  account to one of the major co 
morbidities in children with pancreatic defieciency  and poor nutritional status with high 
expected rates of fractures. 
Tests of pancreatic function 
Tests to detect the  pancreatic secretion  by direct stimulation with exogenous hormones 
 The pancreozymin-secretin test: 
This test is based on the assumption that among the patients with cystic fibrosis 
pancreatic damage is the attributable risk factor  that results in  decrease in the capacity of 
the pancreas to secrete fluid, bicarbonate and enzymes.  
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In this test the duodenal juice is collected after an overnight fasting  using a double lumen 
with the first opening at the ligament of Treitz and the second in the gastric antrum while 
continuous suction being applied to get uncontaminated duodenal juice. 
Intravenous injection of secretin along with cholecystokinin is given to stimulate the 
pancreatic secretion , duodenal juice is collected  for 10 minutes. The samples are 
examined for pH, bicarbonate and enzyme activities . This  is the ``gold standard'' test to 
quantify pancreatic function directly  however the invasiveness and cost price of the test 
tend to discourage its routine clinical use(64).  
 
Urine: indirect (tubeless) test of exocrine pancreatic function 
 
The pancreolauryl test 
Fluorescein dilaurate along with mannitol is given as an emulsion after an overnight 
fasting or after 4 hours of fasting for small babies .Panceatic aryl Elastase cleave 
fluorescein from fluorescein dilaurate ,free fluorescein is then absorbed  in  the gut , into 
the circulation and is finally is excreted in urine where it is measured 
spectrophotometrically. Mannitol resists  hydrolysis in the stomach and small intestine 
and is excreted in the urine, where this can be measured enzymatically The flouresceine 
excreted in the urine is an indirect measure of pancreatic esterase activity while mannitol 
in urine is a measure of intestinal uptake. Results of this tests are measured in urinary 
fluorescein to mannitol ratios. These ratios are significantly lower in children with cystic 
fibrosis than healthy children (P=0.0001). The cut off of F:M rato etween pancreatic 
sufficient and insufficiency is 30 with the test sensitivity being 96% and specificity 
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95%.However this test cannot be used to identify  some isolated enzyme deficiencies(65) 
.  
The N-benzoyl-1-tyrosyl-p-aminobenzoic acid test(66): 
N-benzoyl-l-tyrosyl- p-amino-benzoic acid (NBT-PABA), is a synthetic peptide which is  
selectively cleaved by chymotrypsin.  Its excretion also depends on gastric emptying and 
absorption.Hence to quantify this 13c labelled  PABA or PAS (Para amino salicylate) is 
used which follows the same path but not dependent of chymotrypsin). The test is done as 
follows:  
Fasting urine sample before  administration of  15mg/kg PABA and 4.5mg/kg PAS 
followed by 6 hr urine collection is performed.one. PABA and PAS concentrations are 
measured by gas chromatography-mass spectrometry(83). Results are given as an 
excretion index PABA/PAS. “The normal values are >0.6 (0.6±1.4) and CF patients have 
values <0.5”. The results of the test can also be expressed as the percentage of the oral 
dose of NBT-PABA re-covered as PABA in the urine within 6±8 h. In healthy children 
the PABA recovery is more than 66%. Children with CF and exocrine insufficiency have 
results less than 15%. 
 
Measurement of fat in the stool 
Steatorrhea is classically defined as at least 7 g of fecal fat over 24 hours. Steatorrhoea 
can be due to other reasons than pancreatic insufficiency. 
The titrimetric method: 
The 72-hour quantitative fecal fat test is most abundantly performed test world wide to 
assess the pancreatic function. This test is based on saponification of  faeces with 
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ethanolic alkali, liberation of fatty acids with hydrochloric acid, petroleum ether inturn 
extracts these fatty acids, separation of the petroleum ether and acid ethanol by the 
addition of sodium chloride and a small amount of amyl alcohol and estimation of the 
fatty acids in the petroleum ether fractions by titration(67). It indirectly estimates 
pancreatic function . It does not differentiate the different sites at which fat malabsorption 
is prone to occur such as the  hepatobiliary, mucosal, and pancreatic causes for fat 
malabsorption. The disadvantage of this  invstigation is that patients must stop pancreatic 
supplements during this study. The  reason for this time period of 72 hours was  in view 
of the varied stool fat excretion  in a period of 24 hours , day to day which was 
demonstrated byVan de Kamer et al , thus 72 h stool sample is taken for accurate 
determination of stool fat. The important hindering factor experienced by the patients and 
laboratory technicians is the  malodorous nature of the stools. Also, this 72 h collection 
becomes difficult in children when  diarrhea is present due to the polyethylene lining 
present within the napkin(68).. 
Steatocrit method: 
In this  method a stool sample is diluted with deionised water and homogenised and 
centrifuged. After cen-trifugation, the fat and solid layers are measured separately . 
Steatocrit is calculated as fatty layer. 
 This test was ameliorated by acidification of the stool homogenate with perchloric acid 
(5N for maximal acidification)(91) which results in a larger extraction of fat . 
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Microscopic examination. 
A small amount of faeces is mixed with water and examined under high power 
microscopy (. An average of 2.5 fat droplets per high power field is seen in normal stool 
samples.. In CF, a large amount of round fat drops of different sizes can be seen.   
The gold standard tests done for scrupulous  assessment of the exocrine function of the 
pancreas  is via direct measurements with the secretin–cerulein or secretin–pancreozymin 
test.The obstacles encountered with these   direct functional tests are that they often 
carried out only at specialized centers, and they are time consuming and expensive. 
Faecal immunoreactive lipase (IRL) 
Stool samples must be stored at +/-20°C until  analysis.. The lipase concentration  is 
determined immunologically. Faecal IRL concentrations are age dependent. IRL in stool 
samples of patients with CF ranged from 0.03±107 lg/g (median 0.48 lg/g). 
 According to MuÈ nch et al., this test has a high sensitivity (87%) and an excellent 
specificity (97%) to detect pancreatic insufficiency. However, discrepancies in results 
obtained  among  different studies, which could be attributed to the  different methods 
used to determine faecal lipase. The faecal IRL test is non-invasive and requires little co-
operation by the patient or his parents in  collecting the stool sample. The test can be 
repeated as many times required to support the diagnosis when the suspicion of exocrine 
pancreatic insufficiency is high. In comparision with most other tests done  to support the 
diagnosis of pancreatic insufficiency such as the  faecal chymotrypsin determination, 72 
hour stool fat excretion  the results of this test is not affected by pancreatic enzyme 
replacement therapy. 
 
 
 
58 
 
 
Fecal elastase for  pancreatic insufficiency 
 
Human pancreatic elastase is a glycoprotein synthesized by the acinar cells in te 
pancreas.It differs from other proteases of pancreas in that , besides extending proteolytic 
action , it mixes with bile salts and neutral steroids in the intestinal lumen thereby help in 
transport of cholesterol and its metabolites in the intestinal lumen. 
 This specific function of elastase is because of the stability during intestinal transit.Since 
elastase in faeces is five times higher than that  in the pancreatic juice, it reflects the 
amount of  pancreatic insufficiency accurately.(55). The results of this test is  unaffected 
by exogenous pancreatic enzyme treatment. 
 In a study done to compare the efficacy of fecal elastase with chymotrypsin ,using a cut-
off of 200 microg elastase-1/g, and fecal chymotrypsin (cut-off: 6 U/g)   ‘stool 
sensitivities of the same  were 100% and 76%, respectively (P < 0.0001 and P < 0.001 
respectively) in severe exocrine pancreatic insufficiency, 89% and 47% respectively (P < 
0.001; P = 0.34, respectively) in moderate and 65% for both in mild pancreatic 
insufficiency. Specificities of elastase-1 and chymotrypsin in stool were 55% and 47%, 
respectively’. In the same study the positive predictive value of fecal elastase with cut off 
ofm  200µ/g of stool  was provided as 50%.. Hence it was concluded that  fecal elastase-1 
is highly sensitive in the diagnosis of severe and moderate exocrine pancreatic 
insufficiency ,and is of significantly higher sensitivity than fecal chymotrypsin estimation 
.Because it is a measure of pancreatic function and not a measure of malabsorption, it is 
not valuable as a measure to monitor the effectiveness of Pancreatic enzyme replacement 
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therapy (55). Although, fecal elastase testing has high sensitivity and specificity in 
detecting severe pancreatic insufficiency in children with CF, this  test performs less well 
for detecting mild or moderate pancreatic insufficiency, and also displays variability with 
repeat testing in this type of patient . Thus, results of fecal elastase testing should be 
combined with clinical observations, including nutritional status and symptoms of 
steatorrhea, to determine the need for PERT. Determination of fecal elastase can be 
performed on a single stool sample that requires no special storage, and does not require 
discontinuation of pancreatic enzymes. Thus, it is more clinically practical than a 72-hour 
collection of fecal fat or secretin stimulation tests. The results of fecal elastase testing 
correlate well with the secretin stimulation test and therefore is the gold standard for 
diagnosis of pancreatic insufficiency (69). The clinical evaluation EL-1 is stable in feces 
at room temperature during 1 week, at 4- 8°C during 1 month and at -22. 8°C for longer 
time. 
 Among the CF patients, in whom the clinical presentation is not very clear the EL-1 test 
may not be very reliable due to significant intra-patient variability. In one clinical study 
stool samples among the the CF subjects were collected for fecal elastase for 7 
consecutive days where in the  intraassay variability in CF patients was found to be 
4.06%(70)  
Fecal elastase as gold  standard 
Food and Drug  administration has recently approved Fetal elastase1  a human 
monoclonal enzyme linked immunosorbent assay (ELISA)  for diagnosing pancreatic 
insufficiency. Among the patients with cystic fibrosis, FE-1 has been  proven  to provide 
excellent results to support the diagnosis  of PI, with a sensitivity of 98% to 100%and a 
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specificity of 93% to 100%, even while patients are taking pancreatic enzyme 
supplements(71). The ELISA is human elastase specific and therefore  exogenous 
pancreatic enzyme supplements, which are of porcine origin, have no effect on the results 
.Human monoclonal elastase satisfies 5/6 criteria for an ideal pancreatic test. It does not 
get degraded during intestinal passage and correlates well with secretin pancreozymin 
test which is the most accurate test for determination of pancreatic function .FE1 is low in 
neonates and reaches normal adult values by age of 2 weeks(55). 
 
 
Treatment of pancreatic insufficiency and outcome 
The goal of  treatment is to normalize digestion, alleviate PEI-related symptoms and 
prevent malnutrition-related morbidity and mortality and disease progression. 
Historically, a low-fat diet has been recommended in PEI to reduce steatorrhea. This 
recommendation has been abandoned in modern dietary counseling in PEI due to the risk 
of aggravating PEI-related weight loss and deficiencies of lipid-soluble vitamins(72). By 
optimization of the PERT dose and supportive treatment with PPI it was observed that 
most PEI patients will tolerate a normal-fat diet. Hence, dietary consultation should 
include advice for sufficient caloric intake and normal fat content. Small, frequent meals 
are usually better tolerated than large, high-caloric meals. Deficiencies of fat-soluble 
vitamins are very common in PEI patients, and vitamin supplementation therapy should 
be given if necessary.  
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Pancreatic enzyme replacement therapy (PERT) in CF –history and current status 
The Pancreatic Enzyme replacement therapy is advocated to be used in Pancreatic 
Insufficiency patients in order  to maximize absorption of the nutrients especially lipids. 
In order to accomplish this goal this it is important to obtain adequate concentration of 
pancreatic enzymes in duodenum when the food is being delivered. In order  to replicate 
this physiologic process  resistance to gastric inactivation is necessary and delivery of 
active enzyme at the the duodenum, where digestion occurs is also a requirement. 
Various  formulations of PERT that were used in the past(73). 
 
1.Pancreatin, is a crude mixture form , which is derived from swine or ox pancreas.Each 
milligram contains 2 USP (United States Pharmacopeia) units of lipase and 25 USP units 
of amylase and protease activity.  
2.Pancrelipase is the other formulation obtained from swine pancreas and is a more 
concentrated and purified enzyme preparation. Each milligram contains more  than 24 
USP units of lipase and 100 USP units of amylase and protease activity. Because of its 
higher enzyme content, pancrelipase formulations are favored over pancreatin 
preparations.  
Currently, the main formulations are immediate-release, enteric-coated microspheres and 
minimicrospheres, enteric-coated microtablets, and enteric-coated microspheres with a 
bicarbonate buffer.  Creon, an enteric-coated formulation of pancrelipase which is most 
studied and approved of all formulations of PERT delivered in the form of 
minimicrospheres. 
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Pancreatic Enzyme replacement therapy should be started if  
1)the patient is known to have 2 CFTR mutations associated with PI 
                            Or 
2) the infant has unequivocal signs or symptoms of malabsorption, while awaiting 
confirmatory test results  
                            Or       
3) an objective test of pancreatic function indicates fat malabsorption(74). 
Patients with supportive laboratory evidence of PI should be started on PERT even in the 
absence of signs or symptoms suggestive of fat malabsorption. Dosing of  PERT is 
adjusted according to the  amount of lipase in the supplements.The  initial dose should 
aim at supplying 40 to 60 IU/minute of lipase activity within the duodenal lumen.  For 
infants,  PERT should be started  at a dose of 2000 to 5000 lipase units for each feeding 
which  approximately amounts to 120 mL. Dose  of the PERT should be adjusted with 
increasing age  to not more than  2500 lipase units per kilogram per feeding with a 
maximum daily dose of 10 000 lipase units per kg per day. Enzyme dose and rate of 
weight gain in relation to caloric intake should be evaluated  and documented at each 
visit to monitor the efficacy of PERT.This is because  the per kilogram dose of PERT and 
the volume of intake will rapidly increase in the first few months of life. PERT doses 
should not be increased beyond the upper limit of the recommended range because 
children are at risk of developing fibrosing colonopathy.  
Monitoring the efficacy of PERT: 
Currently there are no definite guidelines in clinical practice to  monitor the efficacy of 
enzyme replacement therapy and  to determine the  need for dose adjustment. 72 hour 
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stool fat collection, coefficient of nitrogen absorption and various breath tests including 
13C-labeled mixed triglyceride breath test have been described . Despite  the tests for 
definitive diagnosis clinical decision  is the common approach to start on enzyme 
replacement therapy and follow up of patients  as   stool collection is o time consuming , 
tedious and hard, and breath tests are not accessible to all patients due to its non-
availability at all centres(73) 
 
Adverse effects of PERT: 
.Pancreatic enzyme replacement therapy is considered safe with limited adverse events 
when compared to placebo. The most commonly reported side effects for recently 
approved enzymes are headache (6%), dizziness (6%), abdominal pain (9%), and 
flatulence. Historically, hyperuricemia, and hyperuricosuria,dysuria  and uric acid 
crystalluria have also been reported  in cystic fibrosis patients with older 
formulations(74). 
 
 
Scoring Systems used in CF 
Total of 16 scoring systems have been described in literature for  severity of cystic 
fibrosis(75). These are  based on clinical evaluation, radiological and tomographic 
findings.These are grouped under Cysti fibrosis scoring systems(CFSS) 
 Of all these Schwachmann scoring system was a milestone in history of cystic fibrosis 
and is stil used as a classical tool for assessment of severity. This scoring system is based 
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on general activity, nutrition,  physical examination and radiological findings.The lower 
the score, the severe is the disease(76). 
 
NIH scoring  developed in 1973 is critically analysed as simple,immediate and easily 
implemented(77). This included  general condition, pulmonary and gastrointestinal 
manifestations(obstruction, poor absorption, abnormalities, sinusitis, nasal polyps)  and 
complicaations including blood gas abnormalities. 
 
First radiographic scoring was done by Norman and Chrispin based on characteristics on 
chest X ray (78).Following which many other scoring systems have been described which 
included clinical and radiological characteristics of CF. 
 
Scoring based on HRCT findings of bronchiectasis was first developed by Nathanson. 
Higher scores corresponded to higher severity. 
 
The most recently developed scoring system is by Kanga et al(79).It was critically 
analyzed to be simple, inexpensive and easily implemented. .It was designed to assess 
acute exacerbations of the disease, to predict improvement or worsening of pulmonary 
function of patients and to evaluate therapeutic effects. 
 
A new surrogate measure for the seriousness of CFTR mutations, identified as Pancreatic  
Insufficiency Prevalence (PIP) score (80), was newly established and validated (Dorfman 
et al., 2010; Ooi et al., 2011a).This score is not to foresee pancreatic insufficiency, rather 
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to identify severity of CFTR mutation using the information of the prevalence of PI when 
individual mutation is existing in a patient. The PIP score for a specific mutation is the 
ratio between the PI patients resonant the mutation (Total PI), and all PI and PS patients 
(Total PI + PS) carrying the same mutation when in a Homozygous state or heterozygous 
amalgamation with F508del, G551D or class I mutations (bona fide severe mutations). 
For example,621+1G>T has a ratio of 1.00 which indicates that all patients with this 
mutationare PI. Likewise, a ratio of 0.1 R334W mutation means determines that 10% of 
subjects with this mutation are PI. .Nevertheless we did not come across any scoring 
system defined in the literature to foresee the pancreatic insufficiency built on clinical 
manifestations(81). 
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METHODS AND METHODOLOGY 
 
STUDY SETTING 
Department of Paediatrics, Christian Medical College, Vellore 
 
STUDY POPULATION 
Children with diagnosis of cystic fibrosis aged 0-18 years as per inclusion criteria. 
 
TYPE OF STUDY 
Prospective observational descriptive study  
 
STUDY PERIOD 
October 2013 - August 2014 
 
SAMPLE SIZE  
Our primary objective was to study the proportion of pancreatic insufficiency among 
Cystic fibrosis children. Very few studies have looked at the prevalence of pancreatic 
insufficiency in India. Study done at AIIMS, stated that the prevalence of malabsorption 
was 80 %( 108) which is consistent with the data from the west. 
If we calculate the sample size using prevalence as 85% the number of CF patients 
required to study would be 51 based on the formula 
 4 pq/ d ^2, 
Where ‘p’ is prevalence of pancreatic insufficiency ie 85%, 
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‘q’ is (100 – p) ie 15%, 
d is margin of error ie 10 
 
 
IRB and ethics committee approval 
This study was approved by the Institutional Review Board (IRB), IRB Min No.8492, 
dated 9.10.2013 (Annexure 1) 
 
 
 
INCLUSION CRITERIA 
1.Children with diagnosis of cystic fibrosis based on elevated sweat electrolyte >80 
mmol/lit (diagnostic range )by wescor macroduct sweat analyzer.. 
2.Those in whom diagnosis was based on clinical features and borderline sweat electrlyte  
level, (60-80 mmol/lit) , who either had typical features like bronchiectasis and 
pseudomonas colonisation or presence of one of common CFTR mutations on mutation 
analysis 
 
EXCLUSION CRITERIA.  
1. Those children who could not give stool sample for fecal elastase testing. 
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DETAILS OF METHODOLOGY 
Study was done in Paediatric department in Christian Medical college Vellore from 
October 2013  till August 2014.Children diagnosed to have  cystic fibrosis based on 
laboratory and clinical criteria from Paediatric Out patient department and wards who 
visited these areas during study period were enrolled .Patients in whom the diagnosis was 
newly made during period and those known cystic fibrosis patients who attended review 
clinic were enrolled. 
No attempt was made to contact the old patients in the CF database as this may bias the 
results by preferentially recruiting pancreatic insufficient patients,. 
Informed consent was obtained from the parent or guardian of the child and assent from 
the child where applicable. (Annexure 2 -5) Using a structured proforma(Annexure 6) 
information on clinical features and lab investigations was collected which included 
demographic data, clinical features pertaining to gastrointestinal as well as other systems, 
details of treatment. Height and weight percentiles were marked using Agarwal growth 
charts. Fresh stool sample was collected for faecal elastase examination .Stool samples 
were collected for microscopic examination for fat globules if they were  not already on 
pancreatic enzyme replacement 
 
Fecal elastase measurement – Methodology (Annexure 8) 
 
Principle of the test:  
The pancreatic Elastase ELISA is a solid phase enzyme linked immunosorbent assay 
(ELISA)based on a double sandwich technique applying two polyclonal antibodies 
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recognizing several different epitopes on defined species and organ specific human 
pancreatic elastase peptide sequences. The ELISA microplate is coated with antibodies   
directed against human pancreatic elastase binding the pancreatic elastase contained in 
different patient samples or in the standards, respectively. 
    In the next step the second antibody labelled with biotin binds to the immobilised 
pancreatic elastase.To visualise the bound pancreatic elastase, the biotin binds in the 
following step to streptavidin labelled horseradish peroxidase.The peroxidase then 
oxidises the substrate TMB (Tetramethyl  benzidne).This reaction will be stopped by the 
addition of 0.25mmol/L of H2SO4.The developed dye (oxidised TMB) can be measured 
photometrically at 450nm. 
 
Limitations of assay: 
Watery stools from the patients may lead to falsely low readings because of the dilution 
effect 
 Estimation of faecal elastase 1 was done every 2 weeks  in batches . The time taken for 
the test to be performed was 6 hours.  
Expected values: 
range Fecal elastase in µg elastase /g of faeces 
Severe exocrine pancreatic insufficiency <100  
Moderate exocrine pancreatic insufficiency 100-200 
Normal exocrine pancreatic function >200 
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.Another specimen of stool was subjected to microscopic examination for stool fat 
globules.  
 
MUTATION ANALYSIS: 
Genetic testing was done for few patients included in the study. 
CFTR gene mutation  screening for 4 common mutations namely F508del, G551D, 
G542X, 621G2T were done by Amplification refractory mutation system (ARMS) PCR . 
. 
DATA ENTRY AND ANALYSIS 
Data entry was done by Epidata version 3.1 and analysis done by SPSS version 16.0.  
The prevalence of pancreatic insufficiency and demographic groups are presented as 
number and percentage. Bivariate analysis is done for pancreatic insufficiency using chi 
square test with Yates correction. Risk estimates are presented as RR with 95% CI. The 
risk variables,  are included in multivariable regression analysis. P value at 5% level  
considered as significant. 
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RESULTS 
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Following figure shows their state of origin. 
 
 
Total number of patients enrolled are 24. 
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Fig.1.  Gender distribution of subjects. 
  
Out of 24 patients enrolled majority 18/24(75%) were boys and 25% were girls. 
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Fig.2 Age distribution of the children at enrollment  .  
 The average age is 2.5 years +/-11 months 
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AGE AT THE ONSET OF SYMPTOMS 
 
Fig 3.Age at the time of onset of symptoms 
Majority of children were less than one year (54%)  at the onset of symptoms ,median 
age being 8 months. 
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FTT- Failure to Thrive    HPB- Hepatobiliary Disease   DM- Diabetes Mellitus 
Fig.4  Clinical symptom profile. 
All children had recurrent respiratory infections, Other predominant complaints were 
inadequate weight gain and steatorrhoea. 
History of salty taste to kiss was encountered in only one child.  
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Table1.,  Distribution of birth weight . 
Birth weight range in grams Number of Children 
1500-2000 1    (4%) 
2001-2500 4(16%) 
2501-3000 12(50%) 
3001-3500 7(29%) 
 
50% children enrolled in the study had birth weight above 2500gm.Only one child had 
very low birth weight. 
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Genetic profile of CF patients (at least one mutation) 
Table 2., Genetic profile of patients (number 13) 
Mutation Number of CF children 
F508del 4(30%) 
G551D 0 
G542X 0 
621G2T 0 
M4740V 1(7%) 
Mutation not detected 8(61%) 
total 13(100%) 
 
 
Mutation analysis results were available for 13 patients. F508 del was detected in 30%.  
Since mutation testing was done for only 4 common mutations and very few had 
complete sequencing of exons 10&11,   we could not detect the mutation in 61%. 
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Symptoms of Pancreatic insufficiency 
 
Fig 5. Children with CF who reported  bulky oily stools. 
Out of 24 children enrolled 70% reported  bulky oily stools . However some of them 
were pancreatic sufficient on further testing. 
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Fig 6.,History of malodorous stool 
54% reported  symptom of foul smelling stool. 
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Fig .7. Symptoms of  pancreatic insufficiency other than  bulky, foul smelling 
stools. 
Increased frequency of stools more than thrice a day was reported by majority of patients. 
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Fig.8.Weight centile distribution in children with CF. 
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Fig.9. Height centile in children with CF 
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Fig.10. Signs of  cystic fibrosis  
Clubbing was observed in 65% of children and oedema 4%,while 1% had signs of fat 
soluble vitamin deficiency . 
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Fig.11. Severity of pancreatic Insufficiency . 
Prevalence of pancreatic insufficiency was 62.4%,while 
41.6% of children had severe pancreatic insufficiency 
 number percent 
PS(FE>200) 9 37.5 
Mod PI(FE 100-200) 5 20.8 
SeverePI(FE<100) 10 41.6 
TOTAL 24 100 
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COMPARISION OF PANCREATIC INSUFFICIENT GROUP WITH 
PANCREATIC SUFFICIENT GROUP  
Pancreatic insufficiency and ∆F508 mutation 
Table 3  PI F508 del mutation 
 ∆F508mutation 
present 
∆F508mutation 
absent 
TOTAL 
PI(FE<=200) 4 9 15 
PS(FE> 200) 0 9 9 
TOTAL 4 18 24 
 
All Children in whom atleast one F508del was detected were pancreatic insufficient. 
Only I child had the mutation in homozygous state. 
 
 
 
 
 
88 
 
 
 
 
 Freq<3/day Freq>=3/day total  
P=0.01 PI( FE<200) 2(33.3%) 13(86.6%) 15(100%) 
PS(FE>200) 6(66.6%) 3(33.33%) 9(100%) 
TOTAL 8 16 24 
 
Fig.13.,Frequency of stools vs pancreatic insufficiency. 
History of passing more than 3 stools per day was significantly associated with pancreatic 
insufficiency. 
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Pancreatic Insufficiency vs Bulky Oily Stool 
 
Fig.12.proportion of PI patients with bulky oily stools. 
73.3% Pancreatic Insufficient children  had bulky oily stools as a predominant symptom 
 Bulky & Oily 
Stools 
No Bulky & 
Oily Stools 
Total  
 
P=0.06 
PS (FE>200) 3 (33.3%) 6(66.7%) 9 (100%) 
PI (FE<=200) 11(73.3%) 4 (26.7%) 15(100%) 
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Pancreatic Insufficiency vs Foul Smelling Stool (FSS) 
 
Fig.14. represents proportion of children with foul smelling stools among CF 
children 
 Statistically significant proportion of children had history of passing malodorous stool 
 FSS present  FSS absent Total  
 
P=0.02 
PI FE <=200 10 (66.7%) 5 (33.3%) 15 (100%) 
PS FE > 200 1 (11.1%) 8 (88.9%) 9 (100 %) 
Total 11 13 24 
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Pancreatic Insufficiency vs Abdominal bloating(ABN) 
 
Fig.15.  Pancreatic insufficient CF children with abdominal bloating. 
There was no statistically significant difference in abdominal bloating symptom  between 
PI and PS patients  
 ABN Present ABN absent Total  
 
P=0.3 
PI FE <=200 6 (40%) 9 (60%) 15 (100%) 
PS FE > 200 2 (22.2%) 7 (77.8%) 9 (100 %) 
Total 8 15 24 
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Pancreatic Insufficiency vs Abdominal Pain(ABP) 
 
Fig.16. Proportion of children with abdominal pain 
Abdominal pain with steatorrhoea was complained only by PI patients, 
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Pancreatic Insufficiency vs Inadequate Weight Gain(IWG) 
 
Fig.17., History of inadequate weight gain as reported by parents in PI and 
PS  cystic fibrosis patients 
There was no statistically significant difference between the 2 groups in terms of 
inadequate weight gain. 
 Inadequate 
weight gain   
Adequate weight 
gain   
Total  
 
P=0.2 
PI FE <=200 12 (80%) 3 (20%) 15 (100%) 
PS FE > 200 5 (55.6%) 4 (44.4%) 9 (100 %) 
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Pancreatic Insufficiency vs Weight Percentile(WP) 
 
Fig 18., Exocrine pancreatic status and weight centile of CF patients. 
Body weight of   all  PI children (100%)  were below 5
th
 centile on Agarwal chart. 
 0 - 5 Centile 5 – 95 Centile Total 
PI FE <=200 15 (100%) 0 (0%) 15 (100%) 
PS FE > 200 6 (66.7%) 3 (33.3%) 9 (100 %) 
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Pancreatic Insufficiency vs Height Percentile(HP) 
 
Fig.19. Exocrine pancreatic status and height centile 
There was no significant difference between PI and PS patients in height centile. 
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P=0.09 
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PS FE > 200 4 (44.4%) 5 (55.6%) 9 (100 %) 
Total 12 12 24 
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Pancreatic Insufficiency vs Age at onset of symptoms 
 
Fig.20. represents relationship of PI with age at  diagnosis 
66.6% of children were less than 1 year during the onset of symptoms with median age 
being 8 months. 
 Age <= 1 year Age > 1 year Total  
 
P=0.2 
PI FE <=200 10(66.6%) 5(33.3%) 15 (100%) 
PS FE > 200 3(33.3%) 6(66.6%) 9 (100 %) 
Total 13 11 24 
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Pancreatic Insufficiency vs Birth weight (BW) 
 
Fig.21., represents relationship of PI with birth weight of CF children 
33.3% of  children with pancreatic insufficiency were of low birth weight i.e. BW< 2500 
grams. 
 BW <= 2500  
( in grams) 
2500 < BW 
<=3500 
(in grams) 
Total  
 
P=0.3 
PI FE <=200 5 (33.3%) 10 (66.6%) 15 (100%) 
PS FE > 200 1 (11.1%) 8 (88.9%) 9 (100 %) 
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Pancreatic Insufficiency vs Delayed Passage of Meconium(DPM) 
 
Fig.22.,Exocrine pancreatic status and history of delayed Passage of Meconium (DPM) at 
birth 
 26.7% historically had delayed passage of meconium at birth. One among the four 
patients had meconium ileus requiring surgery in neonatal period. 
 DPM Present DPM absent Total  
P=0.6 PI FE <=200 4 (26.7%) 11 (73.3%) 15 (100%) 
PS FE > 200 0 (0%) 9(100%) 9 (100 %) 
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Pancreatic Insufficiency vs Fat globules on stool microscopy (FG) 
 
Fig.23. PI  and  stool microscopy for fat globules. 
 83.3% of PI children had numerous fat globules on stool microscopy but there was no 
statistically significant difference from those who were pancreatic sufficient. 
 
 Fat  Globules 
Present 
Fat Globules 
Absent   
Total  
 
P=0.5 
PI FE <=200 10 (83.3%) 2 (16.7%) 12 (100%) 
PS FE > 200 3 (60%) 2 (40%) 5 (100 %) 
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Bronchiectasis was assessed by imaging. All patients had chest X ray and 11   patients 
had High resolution CT of chest. Bronchiectasis could be diagnosed in 55.5% PS and 
44% PI patients with no statistical difference between the 2 groups. As many patients 
were infants bronchiectasis may not have developed and  this assessment may not have 
been optimum. 
 
Relation between pancreatic insufficiency and clinical severity of CF 
Deaths and long term oxygen therapy(LTOT) 
 death LTOT  
PI(FE<=200) 2 2 
PS(FE>200) 0 0 
 
Table 4 Exocrine pancreatic status and poor outcome of CF 
2 children in the pancreatic insufficient group were on long term home oxygen and died 
during the study .Pancreatic sufficient children did not need oxygen at home and there 
was no reported mortality. 
 
 
 
 
101 
 
Table5  CF related diabetes mellitus (CFRDM) use total and % 
 CFRDM present CFRDM absent 
PI(FE<=200) 2 13 
PS(FE>200) 0 9 
 
2 patients in the pancreatic insufficient group required insulin therapy . 
 Fig 23 Severity of disease based on Cooperman score (annexure 7)and its relation to 
pancreatic insufficiency 
 
Using Cooperman score(Annexure 7) ranging from 0-10 (0 being worst and 10 being 
best) 94% of Pancreatic insufficient children had lower scores and 80% pancreatic 
sufficient group had higher score. This difference was statistically different p=0.04.  
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Pancreatic insufficiency vs pseudomonas colonisation 
 
Fig24,Pancreatic  insufficiency and pseudomonas colonisation. 
Pseudomonas colonisation marks the decline of pulmonary function in CF patients. There 
was no statistical difference between PI and PS patients in presence of pseudomonas 
aeruginosa in airway secretions. 
 Pseudo.colonisation No.pseudo 
colonisation 
Total  
 
P=0.2 
PI(FE<=200) 7(46.6%) 8(53.3%) 15(100%) 
PS(FE>200) 5(55.5%) 4(45.5%) 9(100%) 
Total 12 12 24 
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Pancreatic insufficiency and high sweat electrolyte concentration 
 
Fig 25., Exocrine pancreatic status and  sweat electrolyte level. 
Highly elevated sweat electrolyte level was seen in both groups equally. 
It was noted that in the pancreatic insufficient group majority (66%) had values < 
100meq/lit. 
 Sweat e-<100 Sweat e->=100   
 
P=0.2 
PI(FE<200) 10(66.6%) 5(33.33%) 15(100%) 
PS(FE>200) 7(87.5%) 1(12.5%) 8(100%) 
Total 17 6 23 
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Development of a clinical score to predict pancreatic insufficiency 
Table 6., Bivariate analysis for potential  variables using chi square test with 
Yates correction.   
Variables P value Significance(RR) 95% CI 
Foul smelling stool 0.02 16 1.5-166 
Age at presentation 
< 5years 
0.01 13 1.7-99.3 
Frequency of 
stool>=3/day 
0.01 13 1.7-99.3 
Inadequate weight 
gain 
0.2 3.2 0.5-19.8 
Bulky oily stool 0.06 5.5 0.9-33.1 
Abdominal 
distension 
0.3 2.33 0.3-15.3 
Height centile 0.14 4 0.6-25.9 
clubbing 0.08 5.2 0.8-34.4 
Presence of fat 
globules 
0.3 3.33 0.3-34.8 
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Table 6 . represents results of  the multivariate regression analysis for 
significant variables 
 
Significant variables P value Relative Risk 95% CI 
Foul smelling stools 0.15 9.8 (0.42-226.2) 
Frequency of stools 
>=3 per day 
0.56 2.2 (0.14-34.5) 
Age of child at 
diagnosis 
0.06 10.7 (0.8-139.9) 
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DISCUSSION 
Cystic fibrosis ,once considered a disease of the caucasians is increasingly being 
recognised and diagnosed in Indian children. While we do not have exact data on 
prevalence certain estimates have been made.  Even if the incidence is as low as 1 in 
40000 - as estimate based on migrant population data in the US- considering the vast 
population in India, children with cystic fibrosis living in India  may  outnumber those in 
many western countries. 
One of the main problems in India is under diagnosis of the condition even when 
classical features are  present . Delayed  diagnosis  leads to increase in morbidity, 
wasteful expenditure on incorrect  and unnecessary treatment  and rapid progression of 
the disease. Cystic fibrosis is the commonest cause of pancreatic insufficiency. However   
many paediatricians and even gastroenterologists do not evaluate the child adequately to 
rule out cystic fibrosis, even when they recognise pancreatic insufficiency/ fat mal 
absorption.  
This prospective observational study was carried out in a tertiary care centre to addresses 
some of the questions about pancreatic insufficiency  in  CF children in India. 
Prospective nature of the study provided us an opportunity to collect good quality data on 
history and examination of these patients. Consecutive patients utilising the CF clinical 
service of Paediatric department who satisfied the inclusion criteria were recruited to the 
study thereby avoiding a selection bias. 
Through this study we attempted to study manifestations of pancreatic insufficiency in 
our cystic fibrosis population, to find out the proportion of children who are  pancreatic  
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insufficient (PI) using a sensitive and specific test - Faecal elastase. It was also our 
objective to compare the differences between the pancreatic sufficient (PS) and 
pancreatic insufficient (PI) groups in  terms of presenting features , severity of lung 
involvement and other CF manifestations.   
24 consecutive  CF patients who  attended our paediatric service areas during the study 
period were included in the study. This group was comparable to other case series 
reported from other parts of India in terms of demographic data ,disease presentation , 
anthropometric indices and disease severity.  
75% of this series were boys. Most   case series from India show a male 
predominance(16)  . Globally girls with CF are noted to have a worse outcome and life 
expectancy is lower for females (82) .Since this is not a study planned to assess the 
survival benefit of any sex we cannot claim that the higher  proportion of boys in this 
study is due to  better survival of males. It may be just representing the health seeking 
behaviour of the population where male children are  provided better health care than 
girls.  
 
Only 1 child was born with very low birth weight and   majority (79%)had  satisfactory 
birth weight above 2500gm. Malnutrition sets in after the neonatal period as shown by 
research in developed counties comparing data before and after initiation of neonatal 
screening programme(62). 
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In keeping with observation from other centres  ,we also noted a significant delay  in 
making the diagnosis. While age at diagnosis for our population was 76 months, studies 
done at New Delhi(16) and Chandigarh,(1)  age at the time of diagnosis were 54 and 57 
months, respectively.  
 
The average delay in diagnosis was 47 months from the onset of symptoms This is 
similar to the study done by Kabra et al. where the average gap between the onset of 
symptoms and diagnosis was 44 months..  This information obtained from the medical 
records/history by parents   may not be exact and there is bound to be variability. Even 
then,it is evident that there is low index of suspicion for the disease in India and need 
there is need increased awareness for same(16). 
 
50% of the subjects had pseudomonas colonization of airways at the time of recruitment.. 
This is similar to  Study done in AIIMS that showed 50% patients already had 
pseudomonas colonization in their airway at the time of diagnosis(16). Study done in 
Kashmir showed 33.3% of patients colonized with pseudomonas aeruginosa and 33.3% 
colonized with Staphylococcus aureus(1). 
 
 In our series of cystic fibrosis children, predominant  clinical features at presentation  are 
failure to gain weight (80%), recurrent respiratory infections (100%) and history 
suggestive of mal absorption similar to the data  from  PGIMER Chandigarh which  
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showed  statistics of 94% failure to thrive and 74% recurrent or persistent respiratory 
tract infection at the time of presentation. 
Blackman et al (29) reported an incidence of  7-13% meconium using the data collected 
by Twin and Study in United states in sibilings of CF children, monozygotic and 
dizygotic twin. 
There was only 1 child who had meconium ileus surgery in our cohort. History of 
meconium ileus  equivalents i.e., delayed passage of meconium was reported  in 16% of 
patients enrolled in the study. These figures are not comparable as we would have come 
across only CF children who survived the neonatal period  and our figures does not 
represent the true meconium ileus prevalence among CF patients,in a developing country. 
Though salty taste to kiss is taught to medical students as common clinical feature of the 
condition, only  one family reported this symptom. Positive family history of confirmed 
or suspected  CF was present in  only 8%..Other classic   features like rectal prolapse 
(4%,) nasal polyposis (4% ) and pseudobarter  (4% ) presentation  was seen rarely in this 
group. Similar observation was made by researchers elsewhere also.(24,31). 
 
From the above discussion it is evident that  the main presenting features are nonspecific 
like recurrent respiratory infections  and failure to thrive  and the more specific features 
of CF are rarely encountered. However pancreatic insuffciency and fat mal absorption 
which are rare in childhood , when present  should alert one about the possibility of CF 
.This is a pragmatic approach for developing countries like India. It is important to know 
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what percentage  of CF patients have pancreatic insufficiency in India and that was the 
primary objective of our study. 
Best method to answer the above  question will be to identify the total number of CF 
patients in a sample population by neonatal screening and then find out how many of 
them have PI. With no neonatal screening programme in place that method is impractical. 
Hence we resorted to our methodology as a hospital based study. Children who get 
referred to a tertiary care hospital belong to the severe end of the phenotypic spectrum   
of CF, who have mutations causing severe illness .Hence pancreatic insufficiency will be 
overrepresented in this group. In our study the proportion of Pancreatic insufficiency(Fig 
11,) was 62.5% (95% CI-42.7-82.3  ).This is  slightly lower   than the Indian study done 
by Kabra et al (19) where the prevalence of malabsorption was reported as  80%  and 
studies done in NewYork  classify pancreatic insufficient people at  CF centres did show 
a prevalence of 85%(39).   
In an attempt to find the features that  define the clinical profile of  pancreatic deficient 
patients and differentiate them from the PS patients , we compared the 2 groups in terms 
of certain features as below. In  this series history of foul smelling stools and increased 
frequency of stools showed a statistically significant association with pancreatic 
insufficiency. Although 73% of children with PI gave history of  passing bulky oily 
stools compared to33.3 % in PS patients(Fig 12.,)  this did not reach statistical 
significance. Similarly history of abdominal pain and bloating was present in 40% of PI 
and 13% of PS patients. Routine Indian diet   has less fat content than western diet. 
Hence significant steatorrhoea  symptoms like bulky ,oily stools may not be reported in 
many PI patients. In subsequent studies we may need to rephrase the question and ask if 
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these are present when child consumes a fatty meal. Other studies from India did not 
address or report any differences in symptomatology. 
 
Though overall there was a unacceptable delay in diagnosis for most patients,in 
pancreatic insufficient patients diagnosis was made earlier . They were more likely to 
have severe lung disease, need for home oxygen use ,relatively worse growth and more 
likely to have pseudomonas colonisation compared to their PS counterparts. Though 
these findings were not statistically significant in the present study ,it is quite likely that a 
study  with a higher sample size will show statistical significance. Two patients who died 
during the study were pancreatic insufficient. As expected 2  patients  who are on insulin 
therapy for endocrine pancreatic insufficiency (insulin deficeincy) also have exocrine 
deficiency.   
             Pancreatic insufficiency is known to correlate   with malnutrition and therefore 
poor lung function(58) .In our study we found that only 40% of PI children had 
associated bronchiectasis.This can be explained as many of the subjects  included were 
very young in whom  bronchiectasis has not yet developed. As this was not the primary 
objective of the study we did not do HRCT which is the best modality for diagnosis of 
bronchiectasis in all patients . However we used a clinical score  Cooperman score 
(annexure 7) which has been shown to correlate very well with lung function(80) and 
found that PI patient had a lower (worse) score compared to their PS counterparts .This 
difference was statistically significant.        
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              In our study 66.6%(Fig 25) of children with Pancreatic insufficiency had sweat 
electrolyte concentrations less than 100.This observation has been noted in  the literature 
where low sweat chloride concentrations were observed in children with PI due to 
hypoproteinemia causing edema (83). 
Development of a clinical score to predict pancreatic insufficiency was one of the 
secondary objectives of our study. Literature review showed that though there are many 
clinical scores like Shwachman , NIH,Score by Kanga et al(79) to predict severity, 
prognosis etc there are none to predict PI. This may not be a priority in developing 
countries where tests for pancreatic function can be done easily. Pancreatic Insuffiency  
Prevalence (PIP) score predicts  PI when genetic mutation is known(81) However  exact 
determination of the mutation in a given patient is expensive  and impossible for majority 
in a developing country.. Hence a clinical score will be a valuable tool for the clinician in 
India. 
 
We proposed to develop the score by identifying the clinical charecteristics which 
correlate with PI by bivaiate logistic regression and then computing a score ,by 
multivariate logistic regression and plotting  ROC curve sing  Relatve risks of 
independent significant variables. However  we were able to recruit only 24 patients to 
our study applying the inclusion criteria. This number was inadequate for the 
development of a score .Neverthless  we identified 2 variables namely frequency of 
stools(>=3/day), foul smelling stools  as having a high RR for being associated with PI. 
In addition  few others like  presence of bulky oily stool, abdominal bloating may be 
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candidate variables which can be used in the score. We propose to continue this study for 
an extended duration till we have enough number of subjects for this purpose. 
. 
 
. 
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LIMITATIONS 
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Limitations: 
1.This prospective observational study was done on small sample of patients attending a 
tertiary care centre. Due to referral bias pancreatic insufficiency may be over represented 
in this group. 
2. As the duration of study was very short ,sample size could not be reached. We could 
not meet  one of the proposed secondary objectives namely development of a  clinical 
sore to predict PI 
3.As few of these patients were already on pancreatic supplements we could not do 
microscopic examination of stool for   fat droplets in them. This simple lab test may have 
the potential to be a screening test and could be used as a variable for clinical score 
development. 
4.Investigations like high resolution chest imaging, mutation analysis were not done for 
all patients due to financial constraints. Hence comparison between the pancreatic 
sufficient and insufficient groups with regard to severity of the lung disease and genetic 
profile is of limited value.There could be some inaccuracies in symptom reporting by 
parents as this is a chronic disease . 
 
. 
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CONCLUSIONS 
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Conclusions 
 1. In this prospective  study on 24 cystic fibrosis  children who attended  a tertiary 
care centre in South India during the study period  November 2013 to August 2014,   
64% (CI  42.7-82.3  ) had pancreatic  insufficiency as  diagnosed by  low faecal elastase 
level of <200 microgram/gram .  41.6%  of them  had very severe pancreatic 
insufficiency with faecal elastase level < 100 microgram/gram 
        2. If only history suggestive of steatorrhoea was used for identifying children with 
pancreatic insufficiency only 45 %  of these CF children would have been diagnosed as 
pancreatic insufficient. Using faecal elastase test we were able to identify another 19% 
and offer pancreatic enzyme replacement..          
        3..Clinical profile of  these 24 patients   is similar to that described from other parts 
of the world and India with  predominant manifestations of recurrent respiratory 
infections (100%) ,)failure to thrive ( 79 %)  and fat  malabsobtion .Other classic features 
of cystic fibrosis  like meconium ileus,  rectal prolapse, nasal polyposis were seen in only 
a minority of patients.In this cohort median age of onset of symptoms is 8 months while 
that of age at diagnosis is  76 months.  
        4.  All four children in whom F508del mutation was detected were pancreatic 
insufficient. Only 1 child in this group was homozygous for the mutation. 
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        5. During the study period 2 patients from the pancreatic insufficient group died due 
to severe lung disease. Both were less than 2 years of age and were on oxygen therapy at 
home. 
       6.. Pancreatic insufficient group  had lower (worse) Cooperman score for clinical 
severity which was statistically significant. The mean score  of  patients with pancreatic 
insufficiency was 2 .However there was no statistically significant difference  between 
the 2 groups in severity of malnutrition or airway colonisation with pseudomonas 
aeruginosa.  
     7.By bivariate logistic regression  and  multivariate analysis  2 variables were 
identified for computing a clinical score for prediction of pancreatic insufficiency. They 
were history of >/= 3 stools /day and history of malodourous  stools .However due to the 
small number of cases we could not develop the score. 
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RECOMMENDATIONS 
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Recommendations 
1) Increase awareness among medical professional in India about   common 
manifestations of cystic fibrosis in children. Screening for cystic fibrosis should be done 
when fat mal absorption features are present along with recurrent respiratory infections 
 . 
2) Creation of a  cystic fibrosis registry of CF patients of Indian origin is highly 
recommended as each centre has only limited number of cases.. Research using  such a 
large database will provide  answers to questions regarding early identification and 
optimal management of these children in a developing country. 
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ANNEXURE - 2  
INFORMED CONSENT 
Study to estimate the proportion of Pancreatic insufficiency in children with cystic 
fibrosis and develop clinical scoring to predict pancreatic insufficiency in CF 
children 
                                          
                                          Information sheet 
You are being requested to participate in a study to find out the proportion of  children 
with pancreatic insufficiency among those diagnosed to have  cystic fibrosis using a 
special stool test –faecal elastase1. We hope to include about 60 children from this 
hospital in this study. 
Why are we doing the study? 
Cystic fibrosis (CF) is a genetic disorder which affects multiple organs of affected 
patients. It causes  obstruction and infection of airways and indigestion. CF though rare in 
India, affects many children and causes  severe chronic lung disease and pancreatic 
insufficiency. About 85% of children with cystic fibrosis are found to have pancreatic 
insufficiency in western studies. In our country tests to identify pancreatic insufficiency 
are not regularly done as they are costly and available only in few places.  It is proven 
that early identification of pancreatic insufficiency and appropriate treatment for the same 
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would improve the lung function and quality of life in children with cystic fibrosis. In 
future we may be able to detect the children with pancreatic insufficiency based on major 
clinical symptoms and start early treatment. 
What is your role in the study? 
If you agree to participate in this study, your child will be submitted to a questionnaire 
which includes medical history and examination with specific regard to pancreatic 
insufficiency. We will test stool for fecal elastase which is low in children with 
pancreatic insufficiency .We will also include blood tests and simple stool test that 
provides us an additional clue for pancreatic insufficiency. No special preparation is 
necessary for the above tests. 
Will you have to pay for the test? 
Tests which are done for routine care of the patient will have to be paid. However stool 
elastase test can be done at a subsidised rate for study patients. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way.  
What do I benefit from the study? 
You may  benefit from the results of the study. If we identify that your child has 
pancreatic insufficiency he/she can be started on pancreatic supplements which will 
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improve your childs nutritional status. This in addition has been found to improve your 
childs lung status . 
The scoring system we develop from this study will help to identify patients with 
pancreatic insufficiency even when costly tests cannot be done. 
.Will your personal details be kept confidential? 
The results of this study may be published in a medical journal or shared in a scientific 
meeting. However you will not be identified by name in any publication or presentation 
of results. Your medical notes may be reviewed by people associated with the study, 
without your additional permission, should you decide to participate in this study.  
If you have any further questions, please ask  
Dr. M. Archana Mitra (0416-2283343),  
Dr. Sneha Varkki (0416-2283343) 
Dr. Arul Lionel (0416 2283350)  
email: child3@cmcvellore.ac.in 
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ANNEXURE - 3 
CONSENT TO TAKE PART IN A CLINICAL TRIAL 
Study Title: Pancreatic insufficiency in children with cystic fibrosis and clinical 
scoring to predict pancreatic insufficiency in children with cystic fibrosis 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, father/ mother/ guardian   of _____________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provided to me regarding this study 
and have clarified any doubts that I had. [ ] 
Declare that the information sheet has been read to me regarding this study and I 
have clarified any doubts that I had.[ ] 
I also understand that my child’s participation in this study is entirely voluntary 
and that I am free to withdraw permission to continue to participate at any time 
without affecting my child’s usual treatment or his/her legal rights [ ] 
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I understand that the study staff and institutional ethics committee members will 
not need my permission to look at my child’shealth records even if I withdraw from 
the trial. I agree to this access [ ]  
I understand that my child’s identity will not be revealed in any information 
released to third parties or published [ ]   
I voluntarily agree for my child  to take part in this study [ ].I hereby give 
permission for stool examination of my child for fecal elastase. 
 
Name: 
Signature: 
Date:                                                                                                Area for thumb 
impression 
                                                                                                  
                                                                                                          
Name of witness: 
Relation to participant: 
Date: 
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ANNEXURE - 4  
CHILD’S ASSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: Pancreatic insufficiency in children with cystic fibrosis and clinical 
scoring to predict pancreatic insufficiency in children with cystic fibrosis 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
(Please tick boxes) 
Declare that I have read/read to me the information sheet provide to me regarding 
this study and have clarified any doubts that I had. [ ] 
I also understand  my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting 
my child’s usual treatment or his/her legal rights [ ] 
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I understand that the study staff and institutional ethics committee members will 
not need my permission to look at my health records even if I withdraw from the 
trial. I agree to this access [ ]  
I understand that my identity will not be revealed in any information released to 
third parties or published [ ]   
I voluntarily agree  to take part in this study [ ].I hereby give permission for my 
stool examination  for fecal elastase. 
 
Name: 
Signature: 
Date: 
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                                                     ANNEXURE – 5 
TAMIL CONSENT 
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ANNEXURE - 6  
PROFORMA                                      
NAME:                                               Hosp No.                                   Date  
AGE (DOB): 
SEX 
ADDRESS 
SYMPTOMS                                                                       Age first noted 
Meconium ileus, intestinal obstruction                                   yes / no 
Malabsorption  - oily stools                                                     yes / no 
Failure to thrive, malnutrition                                                 yes / no 
Rectal prolapse                                                                        yes / no 
Salty taste                                                                                 yes / no 
Salt craving                                                                              yes / no 
Hepatobiliary disease                                                               yes / no 
Metabolic alkalosis /pseudobartter                                          yes / no 
 
 
 
 
145 
 
Recurrent dehydration                                                             yes / no      
Diabetes mellitus ( > 10yrs) 
Others  
Birth weight                                           current weight 
∆weight loss 
Symptoms of failure to thrive                                                 yes/no 
Gastrointestinal symptoms: 
Foul smelling stools 
Bulky  and oily stools 
Frequent stools more than twice per day        yes/no 
Abdominal distension 
Recurrent abdominal pain 
Nausea and vomiting 
Number of hospital admissions for diarrhoea in the past   
History of documented hypoglycaemia 
Symptoms related to fat malabsorption 
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History of fractures 
Treatment History:                                               Duration 
Pancreatic supplements                                                 yes / no  
How long after Dx  treatment started 
ATT given  
Vitamin supplements 
Anti acid drugs 
Anti reflux drugs                              
Family History 
Family history of pancreatitis                                         yes / no 
Male Infertility                                                                yes / no 
Environmental factors 
Smoking                                                                          yes / no 
Examination: 
Growth:                            Centile       
                                                     
Weight- 
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Height- 
BMI 
Chest circumference 
Head circumference if < 2 years 
Mid arm circumference 
Skin fold thickness 
General examination 
Vitamin deficiencies: 
Vitamin A                                                            yes / no 
Vitamin D                                                            yes / no 
Clubbing                                                               yes / no 
Edema                                                                   yes / no 
Epigastric  mass/tenderness                                  yes / no 
Investigations 
Sweat Chloride test 
 Haemoglobin 
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Serum albumin 
PT, aPTT 
Chest X-ray                                                                                                                                                                                                                
Serum Calcium 
Vit D level 
CFTR Mutation   
Stool fat globules                                                             
Fecal elastase 
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ANNEXURE - 7 
COOPERMAN SCORE 
CATEGORIES 2 1 0 
Activities Normal upon 
physical exertion;  
Engages in typical 
physical activities 
Regular school 
attendance 
(maximum, 2 
absenses/month) 
 
Chest X-ray Normal Slightly increased 
markings; 
Emphysema 
 
Digital Clubbing 0 to 1+ 1 to 2+ 2+ (extensive) 
Growth and 
Development 
Height and Weight 
above the 25th 
percentile 
Height and Weight 
above the 3rd 
percentile 
Height and Weight 
below  the 3rd 
percentile 
Complications None Transitory perpetual 
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                                                ANNEXURE 8 
                                     METHODOLOGY OF FECAL ELASTASE 
 
Reagents needed for test 
1) Reference standard set per vial-0.7ml 
--Standard 1- 50µg elastase/g 
--Standard 2- 100µg elastase/g 
--Standard 3- 200µg elastase/g 
--Standard 4 -500µg elastase/g 
2) Control 1( equivalent to 90µg elastase/g +/- 20%) containing 0.2% sodium azide- 
0.7ml 
3) Control 2(equivalent to 200µg elastase/g+/-20%) containing 0.2% sodium azide-
0.7ml 
 
4) Washing solution ( 10X concentrated) - 2X 50ml 
 
5) Extraction buffer (10X concentrated)- 50ml 
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6) Biotinylated elastase antibody- 0.12ml 
 
7) Streptavidin peroxidase conjugate- 8ml 
8) Substrate solution of TMB- 13ml 
 
9) Stop solution of H2SO4- 13ml 
 
10) Microstrips coated with polyclonal anti elstase antibody 
 
Specimen Collection and storage:  Fresh stool sample are collected for faecal elastase 1 
testing. Samples are transported to lab immediately and stored at different temperatures 
for the following time spans. 
Environmental temperature up to 40°C or 104°F for up to five days. 
Refrigerator temperature 2°C -8°C(36°F-46°F) for upto one week. 
Household freezer temperature -18°C_-20°C(0°F to -4°F) for upto one year. 
 
 Preparation of Faeces sample: 
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Preparation of Extraction buffer: The Extraction buffer is diluted with distilled or 
deionised water in 1: 10 dilution. 
Weighing of Faeces samples: 
A 12ml tube is used with a spatula  to weigh 30-100mg stools on a scale with a sensitivity 
of 1mg. 1ml of extraction buffer per 10mg faeces.The samples are homogenised 
thoroughly with a vortex mixer for 2 minutes.After sedimentation of solid constituents, 
the supernatant can be used for the determination of the elastase after dilution. 
Assay procedure: 
1) The concentrated washing solution must be diluted with 450ml of distilled or de 
ionised water 
2) All the reagents are warmed to room temperature and mixed thoroughly before 
use. 
3) Required number of coated wells or strips in the strip holder are fixed. 
4) The supernatants of extracted faeces are diluted in 1: 201 with washing solution. 
5) 50µL of the blank elastase standards and controls are dispensed each extracted 
and diluted faeces samples wih new disposable tips into wells 
6) These wells are incubated for 60 minutes at room temperature. 
7) The contents are shaken out of the strips and the wells ar rinsed 3 times with 
200µL washing buffer each. 
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8) The residual water is knocked out of the wells by hitting them on absorbent paper 
or cloth 
9) The biotinylated second anti elastase antibody is diluted in 1:201 dilution with 
washing solution 
10) This is incubated for 30min at room temperature. 
11) Later the contents are shaken out of the strips and the wells are rinsed 3 times 
with washing solution, each time using 200µL. 
12) The residual water is then knocked out of the wells by hitting them on adsorbent 
paper or cloth. 
13) 50µL of streptavidin peroxidase conjugate is dispensed into each well. 
14) This is again incubated at room temperature for 30min. 
15) The contents are again shaken out of the strips and the wells are rinsed 3 times 
with washing solution each time using 200µL 
16) The residual water is then knocked out of the wells onto the adsorbent paper or 
cloth 
17) 100µL of substrate solution is dispensed into each well and incubated for 
20minutes at room temperature 
18) Now the enzymatic activity is stopped by adding 100µ of stop solution into each 
well. 
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19) The absorbence of each well is read at 450nm with a microplate reader withi 10 
minutes of stopping the enzymatic reaction. 
 
Pipetting scheme for the pancreatic Elastase ELISA in the lab 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank blank P 2 P 10 P 18 P 26 P 34 
B S 1 P 3 P 11 P 19 P 27 P 35 
C S 2 P 4 P 12 P 20 P 28 P 36 
D S 3 P 5 P 13 P 21 P 29 P 37 
E S 4 P 6 P 14 P 22 P 30 P 38 
F C 1 P 7 P 15 P 23 P 31 P 39 
G C 2 P 8 P 16 P 24 P 32 P 40 
H P 1 P 9 P 17 P 25 P 33 P 41 
 
In the pipetting scheme the recommended positions for the blank (zero standard) , 
standards (S1-S4), Controls (C1 and C2) and for the patients samples (P1-P41) are shown 
as double determinations. 
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                                        ABBREVATIONS 
CF                          Cystic Fibrosis 
PI                            Pancreatic insufficiency 
PS                           Pancreatic Sufficiency 
FE                           Fecal Elastase 
PERT                      Pancreatic enzyme replacement therapy 
CFTR                     Cystic Fibrosis Transmembrane Regulator 
ABP                        Abdominal Pain 
ABN                        Abdominal Distension  
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